A systematic review of brain stimulation in functional seizures Authors: Maryam Moghbel Baerz, Samaneh Zafarabadi, Amir Hossein Rajabi, Zeinab Torbati Aghdam, Mohammadmehdi Naderi, Alireza Zali Published: 2026 ABSTRACT BackgroundFunctional (dissociative) seizures (FDS) are disabling neurological disorders characterized by significant diagnostic and therapeutic challenges. Brain stimulation (BS) techniques are being investigated as potential, neurobiologically-grounded interventions. This systematic review aims to synthesize and evaluate the existing evidence on the therapeutic and diagnostic applications of various BS modalities in patients with FDS.MethodsFollowing PRISMA 2020 guidelines, a systematic search was conducted across PubMed, Scopus, and Web of Science databases from their inception. We included all original research studies, regardless of design, that investigated invasive or non-invasive brain stimulation for therapeutic or diagnostic purposes in patients with a confirmed diagnosis of FDS. Due to substantial clinical and methodological heterogeneity across studies, a narrative synthesis was performed instead of a quantitative meta-analysis.ResultsThe search yielded 4963 records, from which 19 studies (11 therapeutic, 8 diagnostic) met the inclusion criteria after screening. Therapeutic studies, predominantly case reports and small series, indicated that non-invasive techniques such as repetitive transcranial magnetic stimulation (rTMS), intermittent theta-burst stimulation (iTBS), and transcranial direct current stimulation (tDCS) have been associated with reductions in seizure frequency and comorbid psychiatric symptoms in preliminary reports. The right temporoparietal junction (rTPJ) emerged as a commonly targeted region, with preliminary reports suggesting potential benefit. Reported modulation of other regions, including the dorsolateral prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC), lends support to a network-based pathophysiology for FDS. Diagnostic studies confirmed the utility of provocative techniques like photic stimulation in inducing events during video-EEG monitoring. Adverse effects were generally mild and transient, with headache being the most common.ConclusionBrain stimulation, particularly non-invasive modalities targeting key nodes within fronto-limbic-motor circuits, represents a field of significant research interest and a potential future therapeutic avenue for FDS. The evidence supports a shift towards conceptualizing FDS as a heterogeneous network disorder, necessitating phenotype-guided treatment strategies. Future research must prioritize large-scale, sham-controlled randomized clinical trials with standardized protocols and long-term follow-up to definitively establish efficacy and optimize treatment parameters.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12883-026-05021-1. Introduction Functional (dissociative) seizures (FDS), historically referred to as psychogenic non-epileptic seizures (PNES), conversion seizures, or pseudoseizures, are paroxysmal episodes characterized by altered awareness, perception, and behavioral control, typically occurring in the context of emotional or physiological arousal. Subjectively, these events involve distortions of perceptual awareness (e.g., derealization, depersonalization) and are often accompanied by autonomic symptoms such as palpitations or dizziness. Behaviorally, FDS manifest heterogeneously, ranging from akinetic to hyperkinetic presentations where movements, though experienced as involuntary, may reflect innate behavioral patterns or culturally shaped expressions of distress. While older terminology emphasized a purely psychogenic etiology, modern conceptualizations have shifted to a biopsychosocial framework. This model integrates psychological stressors with neural network dysfunction, distinguishing FDS from malingering and aligning with the current consensus on Functional Neurological Disorder [1]. The incidence of FDS was estimated to be 1.4–4.9/100,000/year [2]. Approximately 20–30% of patients referred to epilepsy centers for seizures that are difficult to control are found to have psychogenic non-epileptic seizures (FDS) instead of epileptic seizures [3]. This disorder significantly impacts patients’ lives and impairs their ability to work. The findings of research show that FDS compromises quality of life, notably through increased perceived stigma. A report shows that stigma is strongly associated with poor emotional well-being, seizure worry, and social functioning, showing the complex psychosocial burden of the condition [4]. Functional seizures are frequently misdiagnosed, resulting in inappropriate anti‑seizure medication (ASM) trials and delayed diagnosis. Video‑electroencephalography (vEEG) is the diagnostic gold standard, yet access barriers and a lack of standardized protocols contribute to an average diagnostic delay of 2.8 years (95% CI 2.2–3.5), which is prolonged by empirical ASM use (p = 0.004) [5–10]. This highlights the urgent need for reliable early diagnostic markers and novel interventions that target the underlying network dysfunction. Neuroimaging and electrophysiological studies have demonstrated altered connectivity within fronto‑limbic circuits including amygdala, anterior cingulate, and insula that overlaps with circuits implicated in common psychiatric comorbidities such as depression, anxiety, and PTSD [11–14].This shared pathophysiology supports the investigation of brain‑stimulation (BS) techniques, which modulate these networks and offer a neurobiologically plausible approach to simultaneously alleviate FDS and co‑occurring psychiatric symptoms [7, 8]. Recent neuroimaging studies further support conceptualizing functional neurological disorder (FND), including functional seizures, as a disorder of large-scale brain networks rather than focal pathology [15, 16]. Resting-state and structural MRI investigations that included psychiatric control groups have demonstrated subtle but reproducible alterations in within- and between-network connectivity involving cingulate, frontoparietal, somatomotor, and temporoparietal regions, even after accounting for depression, anxiety, trauma exposure, and medication use [15]. Importantly, subtype analyses suggest both shared and phenotype-specific network features, with functional seizures showing distinct patterns within temporoparietal and default mode regions [16]. Although these studies do not establish diagnostic biomarkers [16] they provide convergent evidence for network-level dysfunction beyond general psychiatric comorbidity, offering a neurobiological framework relevant to neuromodulation-based interventions. Psychotherapy and pharmacotherapy are effective and associated with a reduction in seizure episodes and improved QOL. Available treatments for FDS primarily rely on psychotherapeutic approaches. Cognitive behavioral therapy (CBT) remains the most evidence-based intervention, showing efficacy in reducing seizure frequency and improving quality of life [17, 18].Also, a multicenter CODES RCT found that adding dissociative‑seizure‑specific CBT to standardized medical care did not significantly reduce monthly seizure frequency compared to medical care alone, but did yield clinically meaningful improvements in secondary outcomes, including longer seizure‑free periods, reduced symptom bothersomeness, and better health‑related quality of life [17]. For patients with complex comorbidities, such as those with traumatic brain injury (TBI) and functional seizures, neurobehavioral therapy (NBT) has demonstrated efficacy, significantly reducing seizure frequency and improving mental‑health and disability metrics over 12‑month follow‑up [19]. Pharmacological therapies are generally reserved for comorbid psychiatric conditions instead of FDS itself. At the same time, brain stimulation (BS) has demonstrated therapeutic potential in disorders frequently comorbid with FDS, including depression and anxiety, as well as in epilepsy, where it can modulate irregular neural circuits and reduce seizure burden [20, 21]. These findings provide a translational rationale for investigating brain stimulation as an adjunctive or alternative therapeutic strategy in FDS. Brain stimulation that targets neural networks can modulate functional connectivity among regions such as the prefrontal cortex, the default mode network (DMN), sensorimotor/activation areas, and the cingulate cortex. Consequently, it may affect the frequency and severity of both epileptic and non-epileptic (FDS) seizures [22–24]. Both invasive and noninvasive vagus nerve stimulation (VNS/taVNS) have shown potential to reduce FDS attacks and to induce measurable changes in functional brain connectivity [24–26]. Non-pharmacological approaches, including auricular acupuncture/TEAS, have reported reductions in seizure frequency in preliminary trials, but the evidence remains limited and requires confirmation in larger, controlled study. Likewise, the use of brain stimulation can amplify objective biomarkers for diagnosing and monitoring FDS [27]. As for translational evidence, brain stimulation has shown efficacy in treating seizures and various psychiatric disorders like depression and anxiety, which are commonly associated with FDS [20, 28]. Brain stimulation has shown benefits in epilepsy, where techniques such as vagus nerve stimulation and deep brain stimulation reduce seizure frequency and improve quality of life, particularly in patients with drug-resistant epilepsy [20]. Likewise, in psychiatric disorders including depression and anxiety, transcranial magnetic stimulation and transcranial direct current stimulation have demonstrated meaningful clinical effects on mood regulation and symptom reduction [21]. Since FDS often co-occurs with epilepsy and psychiatric disorders, these findings support the rationale that brain stimulation may also be useful in FDS. These findings provide a basis for further research on the efficacy, safety, and methodological aspects of these methods in humans. In this review, a wide spectrum of brain stimulation modalities for FDS was reviewed. Non-invasive techniques included Transcranial Magnetic Stimulation (TMS), as reported in case studies [29, 30] who studied FDS patients treated with TMS. In addition, Transcranial Direct Current Stimulation (tDCS) has been described in studies [31, 32]. Also short-term stimulation methods like Theta Burst Stimulation have been used in a controlled trial [33] and a case report [34].Photic Stimulation (PS), used as a seizure induction tool during EEG monitoring, was reported in both retrospective and prospective studies [34–36]. Despite these efforts, significant gaps remain. The variety of study designs like case reports, retrospective cohorts, pilot trials have introduced heterogeneity in the results, differences in outcome indicators (e.g., seizure frequency, quality of life, psychiatric symptoms) and stimulation modalities, complicate direct comparisons. No study has comprehensively discussed multiple brain stimulation modalities in FDS for finding effective BS techniques and designing future clinical trials [35–37]. Two systematic reviews have previously evaluated neuromodulation for functional neurological disorders. A 2022 review by Oriuwa et al. synthesized evidence for neuromodulation across the broader spectrum of Functional Neurological Disorder and Somatic Symptom Disorder, finding preliminary promise primarily for TMS in functional motor symptoms [38]. An earlier 2014 review by Pollak et al. focused only on TMS for conversion symptoms, highlighting a lack of placebo-controlled evidence [39].Although previous reviews have evaluated neuromodulation in functional disorders [40]. they are limited by broad inclusion criteria and dated search ranges that exclude recent methodological advances. No review has focused on FDS as a network-based disorder with its own specific brain circuit abnormalities. Furthermore, prior syntheses have not addressed the dual role of brain stimulation as a both possible therapeutic intervention (e.g., iTBS, tDCS) and a diagnostic provocateur (e.g., photic stimulation). By combining the most recent data on all stimulation modalities in FDS, this review fills in these gaps by defining parameters for upcoming confirmatory RCTs and identifying circuit-specific targets. Method This systematic review was conducted and reported in accordance with the Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. We included studies based on the Population, Intervention, Comparators, Outcomes, and Study design (PICOS) framework:Population: Patients of any age with a confirmed diagnosis of psychogenic non-epileptic seizures (FDS) or functional seizures. A diagnosis was considered confirmed if established by video-electroencephalography (vEEG) capturing a typical event In the absence of vEEG, inclusion required a diagnosis of ‘Clinically Established’ or ‘Probable’ FDS according to ILAE guidelines, based on witness accounts, video review, and consensus on semiology by at least two experienced clinicians [8].Intervention: Any form of invasive or non-invasive brain stimulation (e.g., Transcranial Magnetic Stimulation [TMS], Transcranial Direct Current Stimulation [tDCS], Vagus Nerve Stimulation [VNS], Deep Brain Stimulation [DBS], Transcutaneous Electrical Acupoint Stimulation [TEAS], Photic Stimulation) used for therapeutic or diagnostic purposes.Comparators: Any comparator (e.g., sham stimulation) or no comparator.Outcomes: Primary therapeutic outcomes included seizure frequency reduction. Secondary outcomes included improvements in quality of life, reduction in psychiatric comorbidities, and safety/tolerability. Diagnostic outcomes included the diagnostic yield of stimulation techniques.Study Designs: All original research designs, including randomized controlled trials (RCTs), quasi-experimental studies, cohort studies, case-control studies, case series, and case reports, were eligible for inclusion. Review articles, editorials, and conference abstracts were excluded. Population: Patients of any age with a confirmed diagnosis of psychogenic non-epileptic seizures (FDS) or functional seizures. A diagnosis was considered confirmed if established by video-electroencephalography (vEEG) capturing a typical event In the absence of vEEG, inclusion required a diagnosis of ‘Clinically Established’ or ‘Probable’ FDS according to ILAE guidelines, based on witness accounts, video review, and consensus on semiology by at least two experienced clinicians [8]. Population: Patients of any age with a confirmed diagnosis of psychogenic non-epileptic seizures (FDS) or functional seizures. A diagnosis was considered confirmed if established by video-electroencephalography (vEEG) capturing a typical event In the absence of vEEG, inclusion required a diagnosis of ‘Clinically Established’ or ‘Probable’ FDS according to ILAE guidelines, based on witness accounts, video review, and consensus on semiology by at least two experienced clinicians [8]. Intervention: Any form of invasive or non-invasive brain stimulation (e.g., Transcranial Magnetic Stimulation [TMS], Transcranial Direct Current Stimulation [tDCS], Vagus Nerve Stimulation [VNS], Deep Brain Stimulation [DBS], Transcutaneous Electrical Acupoint Stimulation [TEAS], Photic Stimulation) used for therapeutic or diagnostic purposes. Intervention: Any form of invasive or non-invasive brain stimulation (e.g., Transcranial Magnetic Stimulation [TMS], Transcranial Direct Current Stimulation [tDCS], Vagus Nerve Stimulation [VNS], Deep Brain Stimulation [DBS], Transcutaneous Electrical Acupoint Stimulation [TEAS], Photic Stimulation) used for therapeutic or diagnostic purposes. Comparators: Any comparator (e.g., sham stimulation) or no comparator. Comparators: Any comparator (e.g., sham stimulation) or no comparator. Outcomes: Primary therapeutic outcomes included seizure frequency reduction. Secondary outcomes included improvements in quality of life, reduction in psychiatric comorbidities, and safety/tolerability. Diagnostic outcomes included the diagnostic yield of stimulation techniques. Outcomes: Primary therapeutic outcomes included seizure frequency reduction. Secondary outcomes included improvements in quality of life, reduction in psychiatric comorbidities, and safety/tolerability. Diagnostic outcomes included the diagnostic yield of stimulation techniques. Study Designs: All original research designs, including randomized controlled trials (RCTs), quasi-experimental studies, cohort studies, case-control studies, case series, and case reports, were eligible for inclusion. Review articles, editorials, and conference abstracts were excluded. Study Designs: All original research designs, including randomized controlled trials (RCTs), quasi-experimental studies, cohort studies, case-control studies, case series, and case reports, were eligible for inclusion. Review articles, editorials, and conference abstracts were excluded. Search strategy A systematic literature search was conducted in the following electronic databases including PubMed, Scopus, and Web of Science from their inception to July 2025. To reduce publication bias, we also hand‑searched the reference lists of all included studies and relevant review articles. To minimize publication bias we re-ran our literature search to include grey literature sources. In addition, we searched clinical trial registries (ClinicalTrials.gov) and scanned conference abstracts. Search terms used for registry searches were the same root terms used for databases. The complete search strings for all databases are provided in the Supplementary File. Records identified in registries were screened using the same eligibility criteria as for peer-reviewed reports. only studies published in English were included. The search strategy combined keywords and subject headings for two core concepts: (1) FDS and its related terms (e.g., functional seizures, dissociative seizures, non-epileptic attacks) and (2) brain stimulation modalities (e.g., TMS, tDCS, VNS, DBS, TEAS, Photic Stimulation). Search syntax of database search exists in the Supplementary file. Study selection For the screening and study selection process, we used Rayyan QCRI [41].Two reviewers independently screened the titles and abstracts of all identified records against the eligibility criteria using Rayyan QCRI. Subsequently, the full texts of potentially relevant articles were retrieved and assessed for final inclusion by the same two reviewers [Z.A] and [M.N]. Any disagreements at either stage were resolved through discussion and consensus or, if necessary, consultation with a third senior reviewer [M.M]. The study selection process is detailed in the PRISMA flow diagram. Figure 1. Fig. 1Prisma flow diagram Prisma flow diagram Data extraction Two reviewers independently extracted data from the included studies using a standardized data extraction excel form. The extracted information included: (1) study characteristics (first author, year, study design); (2) participant characteristics (sample size, age, gender, diagnostic criteria); (3) intervention details (stimulation modality, parameters); and (4) outcome data (quantitative and qualitative results for therapeutic and diagnostic outcomes). Risk of bias in individual studies The methodological quality of included studies was independently assessed by two reviewers using the appropriate critical appraisal tools from the Joanna Briggs Institute (JBI). The choice of tool was guided by the study design, including the JBI checklists for Randomized Controlled Trials, Cohort Studies, Case Series, Case Reports, Prevalence Studies, and Diagnostic Test Accuracy Studies. Discrepancies in the risk of bias assessments were resolved by consensus. The results of this assessment were used to inform the narrative synthesis of the evidence. Synthesis of results A priori, we planned to conduct a quantitative meta‑analysis if at least three studies reported comparable outcomes for the same intervention and if statistical heterogeneity (assessed by Cochran’s Q test and the I² statistic) was ≤ 75%. However, after full‑text review, we identified substantial clinical and methodological heterogeneity across the included studies. The main sources of heterogeneity were: (1) the wide diversity of study designs (predominantly case reports and small case series); (2) significant variability in brain‑stimulation interventions (target region, frequency, intensity, duration); and (3) inconsistent, non‑standardized reporting of outcome measures. Because the pre‑specified criteria for a meaningful meta‑analysis were not met, a narrative synthesis was performed. This approach allowed us to summarize the evidence without imposing artificial homogeneity and to highlight the distinct patterns and gaps in the literature. Result Study selection A total of 4963 articles were initially retrieved from the database. After removing 2293 duplicates, 2626 studies were excluded in the initial screening stage. Following a full-text review of the remaining 44 articles, 22 were further excluded due to the eligibility criteria. A total of 22 records met the inclusion criteria. Of these, 19 were completed studies reporting clinical outcomes and were included in the risk of bias assessment and data synthesis. The remaining 3 records were clinical trial protocols detailing ongoing research without published results; these are described separately in Table 3 and were excluded from the risk of bias assessment and final synthesis due to the absence of outcome data. The study selection process, distinguishing between database and registry sources, is illustrated in the PRISMA flow diagram (Fig. 1). A summary of the extracted data from these studies is presented in Tables 1 and 2, with Table 1 summarizing treatment strategies and Table 2 summarizing diagnostic approaches. Table 1A summary of therapeutic brain stimulation technique in FDSAuthor, YearCountry / CenterStudy DesignAimInclusion criteriaexclusion criteriaPrior TreatmentsStimulation Modality or Provocation TechniqueDevice & ParametersProtocolOutcome Measures(primary, Secondary)Post-Intervention OutcomesFollow-Up DurationLimitationsMuravsky et al., 2025 [42]USA, University of Pennsylvania and VA Medical CenterCase ReportTo report a previously unassociated side effect of TMS - Functional seizures (FDS) and describe treatment outcomes via acupunctureDiagnosed FDS following TMS; confirmed by EEG.Prior history of epilepsy or seizuresFailed medications (Duloxetine, Lamotrigine, Buspirone.) and psychotherapy; treated via acupuncture.Transcranial Magnetic Stimulation (TMS)MagVenture MagPro-R30 with 70 mm coil; 80% RMT, needle acupuncture at specific points.High-frequency TMS over specific points; acupuncture; TENS unit for home usePrimary: Reduced frequency and duration of FDS episodes. Secondary: Behavioral and psychometric changes; improved quality of life post-acupuncture treatmentFDS frequency reduced from 5/day to < 2/day; duration decreased to less than one minute; one-year recurrence due to stress resolved via reinduction of treatments1 yearAmall sample size (N = 1); single-center, subjective outcome reporting; lack of EEG validation for acupuncture effects.Palmer et al., 2025 [43]USA, Medical University of South Carolina, Charleston, SCCase ReportTo report on the feasibility, safety, and efficacy of synchronized accelerated prefrontal iTBS with taVNS for a patient with co-morbid functional seizures (FS) and treatment-resistant depressionPatient enrolled in a pilot clinical trial with a history of chronic, recurrent treatment-resistant depression and FSs.NRFluvoxamine 100 mg daily, Adderall XR 20 mg daily, clonazepam 0.5 mg twice a day.Synchronized transauricular Vagus Nerve Stimulation (taVNS) and accelerated intermittent Theta Burst Stimulation (iTBS) over the left dorsolateral prefrontal cortex (dlPFC).iTBS: MagVenture X100, Cool B65 coil over F3, 90% RMT, 50 Hz triplet bursts at 5 Hz carrier freq. taVNS: Adhesive hydrogel electrodes on cymba conchae and tragus, 25 Hz, 500 µs pulse width, 7s on / 12s off, at perceptual threshold.6 iTBS/taVNS sessions per day (600 pulses/session) for 8 treatment days, delivered over approximately 2 weeks (6 consecutive days, 5 days off, 2 consecutive days).Primary: Depression scores (PHQ-9, HAM-D). Secondary: Frequency of Functional Seizures (FS).FS: Reduced to 0 for most of the treatment period, with one breakthrough event on day 5. Only 3 FS events in the month following treatment. Depression: At 1-week f/u, PHQ-9 was 8, HAM-D was 10. At 1-month f/u, PHQ-9 was 13, HAM-D was 22.1 week and 1 monthSingle case study; placebo effect cannot be ruled out; unclear if benefit was from iTBS, taVNS, or the combinationVivas et al., 2017 [25]USA, University of South Florida, Tampa, FL; Dartmouth Hitchcock Medical Center, Lebanon, NHRetrospective cohortTo assess quality of life (QOL) after VNS in patients with drug-resistant epilepsy (DRE) and comorbid FDSUnderwent VNS implantation for DRE (2001–2016); vEEG-confirmed epilepsy and FDS; consented and completed post-operative QOLIE-31 and custom improvement survey.Refusal to participate; unreachable; device inactiveVagus Nerve StimulationCyberonics/LivaNova VNS deviceSingle-center VNS implantation by one neurosurgeon; device in situ 2–10 years before survey; post-op QOLIE-31 survey and custom ES/FDS improvement questionnaire administered by phonePrimary: QOLIE-31 overall and subscores (emotional well-being, social functioning, energy/fatigue, cognitive functioning, seizure worry, medication effects). Secondary: patient-perceived % improvement in ES and FDSQuality of life (QOLIE-31) -Mean overall score was 51 ± 8 (on a 0–100 scale), indicating moderate impairment. -Subscales ranged from 34.9 (medication effects) up to 68.4 (emotional well-being) Epileptic seizures (ES) − 8 of 11 respondents (73%) reported at least a 25% reduction in ES frequency. − 4 patients (36%) perceived a major improvement (75–100% reduction) Functional seizures (FDS) - Of the 7 able to tell their FDS apart, all reported improvement. - Over half (57%) reported a 75–100% reduction in FDS episodes2–10 years post-implant (variable)Retrospective design; no pre-operative QOLIE-31 data; no control group; subjective self-report; small sample; variable follow-up; survey unvalidated; possible recall and selection biasesGera et al.,2024 [33]India, Institute of Medical and Health Sciences (Dehradun, India).Randomized, double-blind, sham-controlled pilotTo assess the efficacy of continuous theta burst stimulation (cTBS) over the supplementary motor area (SMA) for reducing FDS frequency and psychopathology (anxiety, dissociation, quality of life)DSM-5/ICD-11 diagnosis of FDS confirmed by video EEG or video monitoring At least 3 dissociative spells/month No psychotherapy in prior month, Age 15–59 ySubstance dependence (except tobacco/caffeine) Prior unprovoked seizure or ECT Implanted metallic devices, Neuroimaging-confirmed neurological illness, Uncontrolled hypertension/diabetes, organ failureContinuous theta burst stimulation (cTBS): 1200 pulses/day for 5 days/week (2 sessions/day, 80% resting motor threshold) over the supplementary motor area (SMA).MagVenture MagPro-R30 with B65 figure-of-eight coil Stimulus intensity: 80% resting motor threshold (RMT) Stimulation delivered at SMA (15% anterior to sagittal midline between inion and nasion)Supplementary Motor Area,15% of the distance between inion and nasion, anterior to the sagittal midline,10 sessions total; 2 sessions/day, 30 min apart, for 5 days/week,1200,80% of Resting Motor Threshold (RMT)Primary Outcome: Frequency of FDS attacks measured in the intention-to-treat (ITT) analysis.Secondary Outcomes: Psychogenic Non-Epileptic Seizure Scale (PNSS): Measures motor phenomena and associated features.Dissociative Experiences Scale-II (DES-II): Assesses dissociative symptoms.Hospital Anxiety and Depression Scale (HADS): Assesses mood (anxiety and depression).WHO Quality of Life-BREF (WHOQOL-BREF): Evaluates quality of life across multiple domains. Clinical Global Impression-Severity (CGI-S): Clinician-rated global severity of illness.Primary Outcome: No significant group × time interaction in FDS frequency across the three evaluation points (F = 0.011; p = 0.998). Secondary Outcomes: No significant changes for total PNSS (F = 0.429; p = 0.654), DES-II (F = 1.865; p = 0.169), or CGI-S (F = 0.239; p = 0.789) on ITT analysis. Within-group analyses in the Active group showed a significant effect on FDS frequency over time (F = 8.93; p < 0.001), although the between-group comparisons did not reach significance.Follow-up at 2 weeks post-intervention for all patientsSmall sample size (n = 11 and n = 9) Single-center pilot trial Lack of long-term follow-up High attrition (n = 3 analyzed: active n = 8, sham n = 8)Minghetti et al.,2024 [44]Italy, Children’s Hospital A. Meyer, Florence (primary); Neurosurgery Dept, Nuovo Arcispedale di Cona, Ferrara; Ospedale Misericordia e Dolce, Pratocase reportTo evaluate feasibility and clinical effects of bilateral subgenual cingulate region (SGC) DBS in drug-resistant conversion disorder with FDS and prolonged catatonia.Early-onset (since age 12) conversion disorder with daily FDS and prolonged catatonia refractory to standard therapies, Severe functional impairment and intellectual declineNRMultiple therapeutic attempts (therapeutic failures), details not specifiedDeep brain stimulation (DBS) of subgenual cingulate regionframe-based (Leksell, Elekta Instruments®, Sweden) technique coupled with a robotic system for stereotactic neurosurgeryBilateral stereotactic implantation under general anesthesia Stimulation started 3 days post-op with stepwise voltage increaseNo OFF-therapy period tested for safetyPrimary: Resolution of FDS and catatonia, Secondary: Improvement in intellectual functioning, social reintegration, neurocognitive performance, quality of lifeImmediate resolution of FDS and catatonia Progressive global improvement and partial social reintegration At 24 months: no FDS/catatonia, enhanced psychotherapy engagement, improved neurocognitive performance and quality of life24 monthsSingle-patient case report, Lack of post-surgical PET follow-up No OFF-therapy testing (risk of rebound) Possible placebo effectLeroy et al., 2023 [31]France, Univ Lille, INSERM, CHU Lille (Lille Neuroscience & Cognition Centre, Plasticity & SubjectivitY Team, CURE PlatformCase seriesTo assess whether cathodal tDCS over the right TPJ reduces seizure frequency in adults with FDSAdults with FDS diagnosed by video-EEG; significant QoL impact; stable pharmacotherapy ≥ 4 wks; persistent FDS ≥ 3 month post-diagnosis announcementPsychotherapy ≤ 4 wks before or during study; history of psychosis/mania; active substance use; meds lowering seizure threshold; pregnancy; changes in pharmacotherapyStable pharmacotherapy ≥ 4 wks; no psychotherapy for FDS during studyCathodal transcranial direct current stimulationNR2 mA (2000 µA); 30 min; cathode at CP6; anode at AF4 | 10 sessions (2/day × 5 days) targeting rTPJPrimary Outcome Weekly seizure frequency, Secondary Outcomes : Depersonalization (CDS), mood/anxiety (HAD), dissociation (DES), somatoform dissociation (SDQ-20), PTSD (PCL-5), physical health (PHQ-15), and alexithymia (TAS-20).Seizures: 0.2 ± 0.3/wk (p = 0.006); no significant change on all secondary scales (all p > 0.05)1 month post-treatmentProof-of-concept case series design.Small sample size (n = 10) Lack of a control group (placebo effect cannot be ruled out) No data on the sustained effect after discontinuation (short follow-up)Peterson et al., 2018 [29]Canada, Neuromodulation and Neuropsychiatry Unit at St. Boniface HospitalCase seriesTo investigate the tolerability and potential efficacy of high frequency (10 Hz) rTMS over the right temporoparietal junction (TPJ) to decrease non-epileptic seizure ratesAdults with convulsive-type Psychogenic Non-epileptic Seizures (FDS) documented by video-EEGComorbid epileptic seizures, major neurological/medical disorders, history of psychosis or mania, active alcohol/drug use disorder, use of seizure-threshold lowering medications (e.g., bupropion), pregnancy, and concurrent psychotherapy.Baseline medications included various psychotropics (Escitalopram, Clonazepam, Lamotrigine, Venlafaxine, Sertraline) and other medications. Changes were minimal during the study.High frequency (10 Hz) repetitive Transcranial Magnetic Stimulation (rTMS).MagStim Rapid-2 with a 70 mm figure-eight coil. Neuronavigation: Brainsight system. Target: Right Temporoparietal Junction (TPJ), Brodmann area 39. Intensity: 110% of resting motor threshold (RMT). Frequency: 10 Hz.Total Sessions: 30 sessions over 3 weeks. Schedule: 2 sessions per day.Pulses per Session: 3000. Train Structure: 5-second trains of 10 Hz pulses, followed by ~ 30 s of rest.Primary: Weekly FDS count via seizure calendar.Secondary: Psychometric scales (DES, SOMS-CD, BDI-II, STAI, SF-36) and tolerability.Statistically significant decrease in weekly seizure rates, sustained at 3-month follow-up. Significant improvement on DES (p = 0.043) and SOMS-CD (p = 0.028) scales. No significant change in BDI-II, STAI, or SF-36.3 months post-treatmentSmall sample size, lack of a sham-controlled group, potential for placebo effect, and uncontrolled comorbid psychiatric conditions and medication use.Agarwal et al., 2019 [34]India, Psychiatry Dept., Shri Guru Ram Rai Institute of Medical & Health Sciences, Dehradun; AIIMS Raipur; Himalayan Inst. Medical Sciences, DehradunCase reportTo describe feasibility, safety, and efficacy of intermittent TBS (iTBS) over right TPJ in a pregnant FDS patientPregnant woman (1st trimester) with recurrent FDS (3–4/day), video-EEG confirmed, normal MRI & labs, refusal of psychotropics due to pregnancyNREscitalopram 10 mg (discontinued 18 m prior to study). No medications during pregnancyIntermittent theta burst stimulation (iTBS)MagVenture MagPro R30; figure-8 coil; 80% resting motor threshold (RMT); site: 1 cm lateral to CP4 (right TPJ); 600 pulses/session10 sessions over 7 days (2/day). Trains: 5s at 10 Hz followed by 30s rest cyclePrimary: FDS frequency reduction (FDS scale scores). Secondary: Mood/anxiety (HAM-D 17, HAM-A scales). Safety metrics included antenatal checksFDS scale: 22 (immediate post), 3 (1wk post). Frequency: 1 attack every 2 days wk1 post, none in wk2–3. HAM-D/A scores improved similarly3 weeks (short-term monitoring)Single-patient design, no control/sham comparison, limited generalizability to non-pregnant populations, potential placebo effect from novel intervention during pregnancyPeterson et al., 2017 [29]Canada; Neuromodulation & Neuropsychiatry Unit, St. Boniface Hospital & University of Manitoba, WinnipegUncontrolled case seriesTo evaluate the tolerability, feasibility, and preliminary efficacy of high-frequency (10 Hz) rTMS over the right temporoparietal junction (TPJ) in reducing seizure frequency in FDS patientsAge 18–65 years, DSM-5 diagnosis of convulsive-type FDS confirmed by video-EEG,≥3 FDS episodes in the month prior to enrollmentEvidence of epileptic seizures or other major neurological disease, Medications lowering seizure threshold (e.g., bupropion) Pregnancy Severe medical illness Comorbid psychotic disorder, bipolar disorder, or active substance use disordermost participants on stable psychotropic regimens (no changes during study)High-frequency (10 Hz) repetitive TMS applied to right TPJMagStim Rapid-2 rTMS machine (MagStim Ltd., UK) with 70 mm figure-8 coil; intensity set at 110% of individually determined motor threshold30 sessions total (3000 pulses/session) Two daily sessions (45 min each) on 15 consecutive weekdays (3 weeks)One subject received three sessions/day over 10 days to accommodate travelTrains: 5 s at 10 Hz followed by 30 s rest; coil placed via neuronavigation on right TPJ (Brodmann area 39)Primary: Weekly FDS episode count at 8 time-points (baseline, weeks 1–3 of treatment; 1 week, 1 month, 2 months, 3 months post-treatment)Secondary: Psychometric scales (DES – dissociation; Conversion Disorder Subscale of SOMS-7; plus mood/anxiety, trauma, resilience, cognitive and functional measures)Significant reduction in weekly FDS frequency over the treatment and 3-month follow-up (RM-ANOVA F = 3.15, p = 0.008)Significant improvements on DES (p = 0.028) and Conversion Disorder Subscale (p = 0.023)Weekly seizure counts through 3 weeks of treatment, then at 1 week, 1 month, 2 months, and 3 months post-treatmentSmall sample, no control arm Unblinded design Single-center recruitment Lack of detailed baseline summary statistics Potential selection bias (referral-based sample) Short follow-up relative to chronic nature of FDSHoomankia et al., 2024 [30]Iran, EMU-linked psychiatry and neurology clinics, Imam Hossein Hospital, Tehran, IranCross-sectional experimentalTo evaluate whether motor threshold (MT) measured by single-pulse TMS/EMG can distinguish FDS from ES and healthy controls, offering a low-cost alternative to VEEGVerified diagnosis (FDS or ES) by experienced neurologist using history + routine EEG; healthy group free of personal/family epilepsy history.all right handedImplanted metallic devices, vagal/cardiac stimulators, pregnancy, ongoing severe neuro/psychiatric illness, other neurological pathologiesES group likely on antiepileptic drugs (AEDs), but specific medications/doses not detailedSingle-pulse transcranial magnetic stimulation (TMS) with EMG recording of motor-evoked potentials (MEPs)Figure-of-eight coil (70 mm internal diameter) connected to two Magstim-200 HP stimulators (Magstim Co., Dyfed, UK) Coil handle perpendicular to skull, 45° mid-sagittal orientation, Stimulation site: left M1 (abductor pollicis brevis hotspot, at C3, 5 cm left of vertex)Determine resting motor threshold (RMT): deliver 10 pulses at varying intensities; the lowest % output eliciting ≥ 50 µV MEP in ≥ 5/10 trials = RMT, Threshold titration: subtract 5 units; if no response, add 2 units until criterion met.5. Monitor full muscle relaxation via audio/visual feedbackPrimary: resting motor threshold (MT) as % of maximum stimulator output Secondary: MEP amplitude (≥ 50 µV)MT did not differ significantly between: ES vs. FDS (P > 0.99) ES vs. controls (P = 0.18) FDS vs. controls (P = 0.37)NRNonrandom, single-center recruitment Modest sample size per arm (n = 24) Right-handed only, Single MT measurement – no test–retest or hemispheric comparisons Non-normal data distribution, TMS metrics (e.g., intracortical inhibition/facilitation) not assessedBlades et al., 2020 [45]USA – Neurological Associates (Los Angeles), UCLA, Theramind (Santa Barbara)Case reportTo evaluate feasibility of fMRI-guided rTMS targeting anterior cingulate in dissociative PTSD presenting with functional dystonia and seizuresActive military with combat trauma; Functional dystonia/seizures confirmed via normal MRI/EEG; Failure of conventional treatments; No structural CNS pathology (ASL normal)Structural brain pathology, Concurrent substance use disorders, PregnancyClonazepam, Baclofen, Sinemet, Flexeril, pain medications; Cognitive processing therapy; Prolonged exposureInhibitory rTMS (1 Hz over 36 sessions)MagVenture MagPro R30; Figure-8 coil; 90% resting motor threshold; Cingulate (primary), SMA (32 sessions), PMC (2 sessions) targets36 sessions over 8 weeks; Real-time fMRI image-guided navigation; 1 Hz stimulation (inhibitory) with intensity adjustments based on pre-TMS mappingPrimary: Symptom remission (GRC = 1). Secondary: BDI-2, GAD-7, PHQ-9, BAI, TWSTRS scoresBDI:4,GAD-7:2,PHQ-9:4,BAI:3,TWSTRS:98 weeks (acute phase) + 3-month follow-up (not quantified)Single-subject design; No sham-controlled comparison; No long-term (> 3mo) assessment; Potential placebo from intensive treatmentGarg et al., 2020 [46]India, (Shri Guru Ram Rai Institute of Medical & Health Sciences, Dehradun; AIIMS, Raipur)Case ReportTo report a case of treatment emergent affective switch (TEAS) in a patient with depression and FDS treated with iTBS over the right temporoparietal junction (rTPJ)Patient had recurrent MDD and FDS with inadequate response to a 3-week medication trialNRTwo prior episodes resolved with mirtazapine (15 mg/d), flupentixol (0.5 mg/d), and clonazepam (0.5 mg/d). Same regimen was inadequate for the current episodeIntermittent Theta Burst Stimulation (iTBS)MagVenture-MagPro-R30 with a figure-of-8 coil. Intensity: 80% of resting motor threshold (RMT). Target: right TPJ (1 cm lateral to CP4).10 sessions total, administered as 2 sessions per day. 600 pulses per session. Treatment was stopped after the 5th session due to adverse eventPrimary: Hamilton Depression Rating Scale (HDRS), FDS scale. Secondary: Young Mania Rating Scale (YMRS) to assess for TEAS.By session 5: HDRS = 3, FDS = 13, YMRS = 18. Day 10 post-rTMS: HDRS = 6, FDS = 1, YMRS = 12.1 monthSingle patient case report, limiting generalizability; lack of a control groupLeroy et al., 2019 [32]France, CHU Lille, France & Université LilleCase reportTo evaluate PET-scan guided tDCS as a treatment for FDS and associated clinical symptoms (dissociation, depression)Patient with treatment-resistant FDS and depression, no prior response to antidepressants, MRI/EEG confirmed absence of epileptiform activityPatient with spontaneous FDS history (n = 2 excluded in Benbadis, but this study included them)Cannabis (daily), amphetamines (weekly), two antidepressants (fluvoxamine, Adderall), no psychotherapyPET-scan guided transcranial direct current stimulation (tDCS)Current intensity: 2 mA, Electrode size: 35 cm², Stimulation duration: 30 min/sessionAnode placement at F3, cathode at FP2, 5 days/week, 2 sessions/day for 3 weeks, Total: 30 sessions (15 days over 3 weeks)Primary: FDS frequency reductionSecondary: Dissociative symptoms (SDQ, DES, CDS), depression (MADRS), alexithymia (TAS), PTSD (PCLS)FDS frequency: 80% reduction (generalized to 1/week, focal to 1/week) - AIMS: 12 (-63%) - MADRS: 16 (-20%) - PCLS: 52 (-31%) - SDQ: 32 (-29%), DES: 34% (-15%), CDS: 59 (-22%) - TAS: 62 (-8%)Improvement sustained for 8 weeks post-treatmentSingle case study, Cannot distinguish tDCS effects from concomitant antidepressants, Long-term efficacy unknown, PET-scan hypometabolism possibly depression-related rather than FDS-specific Table 1A summary of therapeutic brain stimulation technique in FDSAuthor, YearCountry / CenterStudy DesignAimInclusion criteriaexclusion criteriaPrior TreatmentsStimulation Modality or Provocation TechniqueDevice & ParametersProtocolOutcome Measures(primary, Secondary)Post-Intervention OutcomesFollow-Up DurationLimitationsMuravsky et al., 2025 [42]USA, University of Pennsylvania and VA Medical CenterCase ReportTo report a previously unassociated side effect of TMS - Functional seizures (FDS) and describe treatment outcomes via acupunctureDiagnosed FDS following TMS; confirmed by EEG.Prior history of epilepsy or seizuresFailed medications (Duloxetine, Lamotrigine, Buspirone.) and psychotherapy; treated via acupuncture.Transcranial Magnetic Stimulation (TMS)MagVenture MagPro-R30 with 70 mm coil; 80% RMT, needle acupuncture at specific points.High-frequency TMS over specific points; acupuncture; TENS unit for home usePrimary: Reduced frequency and duration of FDS episodes. Secondary: Behavioral and psychometric changes; improved quality of life post-acupuncture treatmentFDS frequency reduced from 5/day to < 2/day; duration decreased to less than one minute; one-year recurrence due to stress resolved via reinduction of treatments1 yearAmall sample size (N = 1); single-center, subjective outcome reporting; lack of EEG validation for acupuncture effects.Palmer et al., 2025 [43]USA, Medical University of South Carolina, Charleston, SCCase ReportTo report on the feasibility, safety, and efficacy of synchronized accelerated prefrontal iTBS with taVNS for a patient with co-morbid functional seizures (FS) and treatment-resistant depressionPatient enrolled in a pilot clinical trial with a history of chronic, recurrent treatment-resistant depression and FSs.NRFluvoxamine 100 mg daily, Adderall XR 20 mg daily, clonazepam 0.5 mg twice a day.Synchronized transauricular Vagus Nerve Stimulation (taVNS) and accelerated intermittent Theta Burst Stimulation (iTBS) over the left dorsolateral prefrontal cortex (dlPFC).iTBS: MagVenture X100, Cool B65 coil over F3, 90% RMT, 50 Hz triplet bursts at 5 Hz carrier freq. taVNS: Adhesive hydrogel electrodes on cymba conchae and tragus, 25 Hz, 500 µs pulse width, 7s on / 12s off, at perceptual threshold.6 iTBS/taVNS sessions per day (600 pulses/session) for 8 treatment days, delivered over approximately 2 weeks (6 consecutive days, 5 days off, 2 consecutive days).Primary: Depression scores (PHQ-9, HAM-D). Secondary: Frequency of Functional Seizures (FS).FS: Reduced to 0 for most of the treatment period, with one breakthrough event on day 5. Only 3 FS events in the month following treatment. Depression: At 1-week f/u, PHQ-9 was 8, HAM-D was 10. At 1-month f/u, PHQ-9 was 13, HAM-D was 22.1 week and 1 monthSingle case study; placebo effect cannot be ruled out; unclear if benefit was from iTBS, taVNS, or the combinationVivas et al., 2017 [25]USA, University of South Florida, Tampa, FL; Dartmouth Hitchcock Medical Center, Lebanon, NHRetrospective cohortTo assess quality of life (QOL) after VNS in patients with drug-resistant epilepsy (DRE) and comorbid FDSUnderwent VNS implantation for DRE (2001–2016); vEEG-confirmed epilepsy and FDS; consented and completed post-operative QOLIE-31 and custom improvement survey.Refusal to participate; unreachable; device inactiveVagus Nerve StimulationCyberonics/LivaNova VNS deviceSingle-center VNS implantation by one neurosurgeon; device in situ 2–10 years before survey; post-op QOLIE-31 survey and custom ES/FDS improvement questionnaire administered by phonePrimary: QOLIE-31 overall and subscores (emotional well-being, social functioning, energy/fatigue, cognitive functioning, seizure worry, medication effects). Secondary: patient-perceived % improvement in ES and FDSQuality of life (QOLIE-31) -Mean overall score was 51 ± 8 (on a 0–100 scale), indicating moderate impairment. -Subscales ranged from 34.9 (medication effects) up to 68.4 (emotional well-being) Epileptic seizures (ES) − 8 of 11 respondents (73%) reported at least a 25% reduction in ES frequency. − 4 patients (36%) perceived a major improvement (75–100% reduction) Functional seizures (FDS) - Of the 7 able to tell their FDS apart, all reported improvement. - Over half (57%) reported a 75–100% reduction in FDS episodes2–10 years post-implant (variable)Retrospective design; no pre-operative QOLIE-31 data; no control group; subjective self-report; small sample; variable follow-up; survey unvalidated; possible recall and selection biasesGera et al.,2024 [33]India, Institute of Medical and Health Sciences (Dehradun, India).Randomized, double-blind, sham-controlled pilotTo assess the efficacy of continuous theta burst stimulation (cTBS) over the supplementary motor area (SMA) for reducing FDS frequency and psychopathology (anxiety, dissociation, quality of life)DSM-5/ICD-11 diagnosis of FDS confirmed by video EEG or video monitoring At least 3 dissociative spells/month No psychotherapy in prior month, Age 15–59 ySubstance dependence (except tobacco/caffeine) Prior unprovoked seizure or ECT Implanted metallic devices, Neuroimaging-confirmed neurological illness, Uncontrolled hypertension/diabetes, organ failureContinuous theta burst stimulation (cTBS): 1200 pulses/day for 5 days/week (2 sessions/day, 80% resting motor threshold) over the supplementary motor area (SMA).MagVenture MagPro-R30 with B65 figure-of-eight coil Stimulus intensity: 80% resting motor threshold (RMT) Stimulation delivered at SMA (15% anterior to sagittal midline between inion and nasion)Supplementary Motor Area,15% of the distance between inion and nasion, anterior to the sagittal midline,10 sessions total; 2 sessions/day, 30 min apart, for 5 days/week,1200,80% of Resting Motor Threshold (RMT)Primary Outcome: Frequency of FDS attacks measured in the intention-to-treat (ITT) analysis.Secondary Outcomes: Psychogenic Non-Epileptic Seizure Scale (PNSS): Measures motor phenomena and associated features.Dissociative Experiences Scale-II (DES-II): Assesses dissociative symptoms.Hospital Anxiety and Depression Scale (HADS): Assesses mood (anxiety and depression).WHO Quality of Life-BREF (WHOQOL-BREF): Evaluates quality of life across multiple domains. Clinical Global Impression-Severity (CGI-S): Clinician-rated global severity of illness.Primary Outcome: No significant group × time interaction in FDS frequency across the three evaluation points (F = 0.011; p = 0.998). Secondary Outcomes: No significant changes for total PNSS (F = 0.429; p = 0.654), DES-II (F = 1.865; p = 0.169), or CGI-S (F = 0.239; p = 0.789) on ITT analysis. Within-group analyses in the Active group showed a significant effect on FDS frequency over time (F = 8.93; p < 0.001), although the between-group comparisons did not reach significance.Follow-up at 2 weeks post-intervention for all patientsSmall sample size (n = 11 and n = 9) Single-center pilot trial Lack of long-term follow-up High attrition (n = 3 analyzed: active n = 8, sham n = 8)Minghetti et al.,2024 [44]Italy, Children’s Hospital A. Meyer, Florence (primary); Neurosurgery Dept, Nuovo Arcispedale di Cona, Ferrara; Ospedale Misericordia e Dolce, Pratocase reportTo evaluate feasibility and clinical effects of bilateral subgenual cingulate region (SGC) DBS in drug-resistant conversion disorder with FDS and prolonged catatonia.Early-onset (since age 12) conversion disorder with daily FDS and prolonged catatonia refractory to standard therapies, Severe functional impairment and intellectual declineNRMultiple therapeutic attempts (therapeutic failures), details not specifiedDeep brain stimulation (DBS) of subgenual cingulate regionframe-based (Leksell, Elekta Instruments®, Sweden) technique coupled with a robotic system for stereotactic neurosurgeryBilateral stereotactic implantation under general anesthesia Stimulation started 3 days post-op with stepwise voltage increaseNo OFF-therapy period tested for safetyPrimary: Resolution of FDS and catatonia, Secondary: Improvement in intellectual functioning, social reintegration, neurocognitive performance, quality of lifeImmediate resolution of FDS and catatonia Progressive global improvement and partial social reintegration At 24 months: no FDS/catatonia, enhanced psychotherapy engagement, improved neurocognitive performance and quality of life24 monthsSingle-patient case report, Lack of post-surgical PET follow-up No OFF-therapy testing (risk of rebound) Possible placebo effectLeroy et al., 2023 [31]France, Univ Lille, INSERM, CHU Lille (Lille Neuroscience & Cognition Centre, Plasticity & SubjectivitY Team, CURE PlatformCase seriesTo assess whether cathodal tDCS over the right TPJ reduces seizure frequency in adults with FDSAdults with FDS diagnosed by video-EEG; significant QoL impact; stable pharmacotherapy ≥ 4 wks; persistent FDS ≥ 3 month post-diagnosis announcementPsychotherapy ≤ 4 wks before or during study; history of psychosis/mania; active substance use; meds lowering seizure threshold; pregnancy; changes in pharmacotherapyStable pharmacotherapy ≥ 4 wks; no psychotherapy for FDS during studyCathodal transcranial direct current stimulationNR2 mA (2000 µA); 30 min; cathode at CP6; anode at AF4 | 10 sessions (2/day × 5 days) targeting rTPJPrimary Outcome Weekly seizure frequency, Secondary Outcomes : Depersonalization (CDS), mood/anxiety (HAD), dissociation (DES), somatoform dissociation (SDQ-20), PTSD (PCL-5), physical health (PHQ-15), and alexithymia (TAS-20).Seizures: 0.2 ± 0.3/wk (p = 0.006); no significant change on all secondary scales (all p > 0.05)1 month post-treatmentProof-of-concept case series design.Small sample size (n = 10) Lack of a control group (placebo effect cannot be ruled out) No data on the sustained effect after discontinuation (short follow-up)Peterson et al., 2018 [29]Canada, Neuromodulation and Neuropsychiatry Unit at St. Boniface HospitalCase seriesTo investigate the tolerability and potential efficacy of high frequency (10 Hz) rTMS over the right temporoparietal junction (TPJ) to decrease non-epileptic seizure ratesAdults with convulsive-type Psychogenic Non-epileptic Seizures (FDS) documented by video-EEGComorbid epileptic seizures, major neurological/medical disorders, history of psychosis or mania, active alcohol/drug use disorder, use of seizure-threshold lowering medications (e.g., bupropion), pregnancy, and concurrent psychotherapy.Baseline medications included various psychotropics (Escitalopram, Clonazepam, Lamotrigine, Venlafaxine, Sertraline) and other medications. Changes were minimal during the study.High frequency (10 Hz) repetitive Transcranial Magnetic Stimulation (rTMS).MagStim Rapid-2 with a 70 mm figure-eight coil. Neuronavigation: Brainsight system. Target: Right Temporoparietal Junction (TPJ), Brodmann area 39. Intensity: 110% of resting motor threshold (RMT). Frequency: 10 Hz.Total Sessions: 30 sessions over 3 weeks. Schedule: 2 sessions per day.Pulses per Session: 3000. Train Structure: 5-second trains of 10 Hz pulses, followed by ~ 30 s of rest.Primary: Weekly FDS count via seizure calendar.Secondary: Psychometric scales (DES, SOMS-CD, BDI-II, STAI, SF-36) and tolerability.Statistically significant decrease in weekly seizure rates, sustained at 3-month follow-up. Significant improvement on DES (p = 0.043) and SOMS-CD (p = 0.028) scales. No significant change in BDI-II, STAI, or SF-36.3 months post-treatmentSmall sample size, lack of a sham-controlled group, potential for placebo effect, and uncontrolled comorbid psychiatric conditions and medication use.Agarwal et al., 2019 [34]India, Psychiatry Dept., Shri Guru Ram Rai Institute of Medical & Health Sciences, Dehradun; AIIMS Raipur; Himalayan Inst. Medical Sciences, DehradunCase reportTo describe feasibility, safety, and efficacy of intermittent TBS (iTBS) over right TPJ in a pregnant FDS patientPregnant woman (1st trimester) with recurrent FDS (3–4/day), video-EEG confirmed, normal MRI & labs, refusal of psychotropics due to pregnancyNREscitalopram 10 mg (discontinued 18 m prior to study). No medications during pregnancyIntermittent theta burst stimulation (iTBS)MagVenture MagPro R30; figure-8 coil; 80% resting motor threshold (RMT); site: 1 cm lateral to CP4 (right TPJ); 600 pulses/session10 sessions over 7 days (2/day). Trains: 5s at 10 Hz followed by 30s rest cyclePrimary: FDS frequency reduction (FDS scale scores). Secondary: Mood/anxiety (HAM-D 17, HAM-A scales). Safety metrics included antenatal checksFDS scale: 22 (immediate post), 3 (1wk post). Frequency: 1 attack every 2 days wk1 post, none in wk2–3. HAM-D/A scores improved similarly3 weeks (short-term monitoring)Single-patient design, no control/sham comparison, limited generalizability to non-pregnant populations, potential placebo effect from novel intervention during pregnancyPeterson et al., 2017 [29]Canada; Neuromodulation & Neuropsychiatry Unit, St. Boniface Hospital & University of Manitoba, WinnipegUncontrolled case seriesTo evaluate the tolerability, feasibility, and preliminary efficacy of high-frequency (10 Hz) rTMS over the right temporoparietal junction (TPJ) in reducing seizure frequency in FDS patientsAge 18–65 years, DSM-5 diagnosis of convulsive-type FDS confirmed by video-EEG,≥3 FDS episodes in the month prior to enrollmentEvidence of epileptic seizures or other major neurological disease, Medications lowering seizure threshold (e.g., bupropion) Pregnancy Severe medical illness Comorbid psychotic disorder, bipolar disorder, or active substance use disordermost participants on stable psychotropic regimens (no changes during study)High-frequency (10 Hz) repetitive TMS applied to right TPJMagStim Rapid-2 rTMS machine (MagStim Ltd., UK) with 70 mm figure-8 coil; intensity set at 110% of individually determined motor threshold30 sessions total (3000 pulses/session) Two daily sessions (45 min each) on 15 consecutive weekdays (3 weeks)One subject received three sessions/day over 10 days to accommodate travelTrains: 5 s at 10 Hz followed by 30 s rest; coil placed via neuronavigation on right TPJ (Brodmann area 39)Primary: Weekly FDS episode count at 8 time-points (baseline, weeks 1–3 of treatment; 1 week, 1 month, 2 months, 3 months post-treatment)Secondary: Psychometric scales (DES – dissociation; Conversion Disorder Subscale of SOMS-7; plus mood/anxiety, trauma, resilience, cognitive and functional measures)Significant reduction in weekly FDS frequency over the treatment and 3-month follow-up (RM-ANOVA F = 3.15, p = 0.008)Significant improvements on DES (p = 0.028) and Conversion Disorder Subscale (p = 0.023)Weekly seizure counts through 3 weeks of treatment, then at 1 week, 1 month, 2 months, and 3 months post-treatmentSmall sample, no control arm Unblinded design Single-center recruitment Lack of detailed baseline summary statistics Potential selection bias (referral-based sample) Short follow-up relative to chronic nature of FDSHoomankia et al., 2024 [30]Iran, EMU-linked psychiatry and neurology clinics, Imam Hossein Hospital, Tehran, IranCross-sectional experimentalTo evaluate whether motor threshold (MT) measured by single-pulse TMS/EMG can distinguish FDS from ES and healthy controls, offering a low-cost alternative to VEEGVerified diagnosis (FDS or ES) by experienced neurologist using history + routine EEG; healthy group free of personal/family epilepsy history.all right handedImplanted metallic devices, vagal/cardiac stimulators, pregnancy, ongoing severe neuro/psychiatric illness, other neurological pathologiesES group likely on antiepileptic drugs (AEDs), but specific medications/doses not detailedSingle-pulse transcranial magnetic stimulation (TMS) with EMG recording of motor-evoked potentials (MEPs)Figure-of-eight coil (70 mm internal diameter) connected to two Magstim-200 HP stimulators (Magstim Co., Dyfed, UK) Coil handle perpendicular to skull, 45° mid-sagittal orientation, Stimulation site: left M1 (abductor pollicis brevis hotspot, at C3, 5 cm left of vertex)Determine resting motor threshold (RMT): deliver 10 pulses at varying intensities; the lowest % output eliciting ≥ 50 µV MEP in ≥ 5/10 trials = RMT, Threshold titration: subtract 5 units; if no response, add 2 units until criterion met.5. Monitor full muscle relaxation via audio/visual feedbackPrimary: resting motor threshold (MT) as % of maximum stimulator output Secondary: MEP amplitude (≥ 50 µV)MT did not differ significantly between: ES vs. FDS (P > 0.99) ES vs. controls (P = 0.18) FDS vs. controls (P = 0.37)NRNonrandom, single-center recruitment Modest sample size per arm (n = 24) Right-handed only, Single MT measurement – no test–retest or hemispheric comparisons Non-normal data distribution, TMS metrics (e.g., intracortical inhibition/facilitation) not assessedBlades et al., 2020 [45]USA – Neurological Associates (Los Angeles), UCLA, Theramind (Santa Barbara)Case reportTo evaluate feasibility of fMRI-guided rTMS targeting anterior cingulate in dissociative PTSD presenting with functional dystonia and seizuresActive military with combat trauma; Functional dystonia/seizures confirmed via normal MRI/EEG; Failure of conventional treatments; No structural CNS pathology (ASL normal)Structural brain pathology, Concurrent substance use disorders, PregnancyClonazepam, Baclofen, Sinemet, Flexeril, pain medications; Cognitive processing therapy; Prolonged exposureInhibitory rTMS (1 Hz over 36 sessions)MagVenture MagPro R30; Figure-8 coil; 90% resting motor threshold; Cingulate (primary), SMA (32 sessions), PMC (2 sessions) targets36 sessions over 8 weeks; Real-time fMRI image-guided navigation; 1 Hz stimulation (inhibitory) with intensity adjustments based on pre-TMS mappingPrimary: Symptom remission (GRC = 1). Secondary: BDI-2, GAD-7, PHQ-9, BAI, TWSTRS scoresBDI:4,GAD-7:2,PHQ-9:4,BAI:3,TWSTRS:98 weeks (acute phase) + 3-month follow-up (not quantified)Single-subject design; No sham-controlled comparison; No long-term (> 3mo) assessment; Potential placebo from intensive treatmentGarg et al., 2020 [46]India, (Shri Guru Ram Rai Institute of Medical & Health Sciences, Dehradun; AIIMS, Raipur)Case ReportTo report a case of treatment emergent affective switch (TEAS) in a patient with depression and FDS treated with iTBS over the right temporoparietal junction (rTPJ)Patient had recurrent MDD and FDS with inadequate response to a 3-week medication trialNRTwo prior episodes resolved with mirtazapine (15 mg/d), flupentixol (0.5 mg/d), and clonazepam (0.5 mg/d). Same regimen was inadequate for the current episodeIntermittent Theta Burst Stimulation (iTBS)MagVenture-MagPro-R30 with a figure-of-8 coil. Intensity: 80% of resting motor threshold (RMT). Target: right TPJ (1 cm lateral to CP4).10 sessions total, administered as 2 sessions per day. 600 pulses per session. Treatment was stopped after the 5th session due to adverse eventPrimary: Hamilton Depression Rating Scale (HDRS), FDS scale. Secondary: Young Mania Rating Scale (YMRS) to assess for TEAS.By session 5: HDRS = 3, FDS = 13, YMRS = 18. Day 10 post-rTMS: HDRS = 6, FDS = 1, YMRS = 12.1 monthSingle patient case report, limiting generalizability; lack of a control groupLeroy et al., 2019 [32]France, CHU Lille, France & Université LilleCase reportTo evaluate PET-scan guided tDCS as a treatment for FDS and associated clinical symptoms (dissociation, depression)Patient with treatment-resistant FDS and depression, no prior response to antidepressants, MRI/EEG confirmed absence of epileptiform activityPatient with spontaneous FDS history (n = 2 excluded in Benbadis, but this study included them)Cannabis (daily), amphetamines (weekly), two antidepressants (fluvoxamine, Adderall), no psychotherapyPET-scan guided transcranial direct current stimulation (tDCS)Current intensity: 2 mA, Electrode size: 35 cm², Stimulation duration: 30 min/sessionAnode placement at F3, cathode at FP2, 5 days/week, 2 sessions/day for 3 weeks, Total: 30 sessions (15 days over 3 weeks)Primary: FDS frequency reductionSecondary: Dissociative symptoms (SDQ, DES, CDS), depression (MADRS), alexithymia (TAS), PTSD (PCLS)FDS frequency: 80% reduction (generalized to 1/week, focal to 1/week) - AIMS: 12 (-63%) - MADRS: 16 (-20%) - PCLS: 52 (-31%) - SDQ: 32 (-29%), DES: 34% (-15%), CDS: 59 (-22%) - TAS: 62 (-8%)Improvement sustained for 8 weeks post-treatmentSingle case study, Cannot distinguish tDCS effects from concomitant antidepressants, Long-term efficacy unknown, PET-scan hypometabolism possibly depression-related rather than FDS-specific A summary of therapeutic brain stimulation technique in FDS Quality of life (QOLIE-31) -Mean overall score was 51 ± 8 (on a 0–100 scale), indicating moderate impairment. -Subscales ranged from 34.9 (medication effects) up to 68.4 (emotional well-being) Epileptic seizures (ES) − 8 of 11 respondents (73%) reported at least a 25% reduction in ES frequency. − 4 patients (36%) perceived a major improvement (75–100% reduction) Functional seizures (FDS) - Of the 7 able to tell their FDS apart, all reported improvement. - Over half (57%) reported a 75–100% reduction in FDS episodes frame-based (Leksell, Elekta Instruments®, Sweden) technique coupled with a robotic system for stereotactic neurosurgery Table 2A summary of diagnostic technique FDS patientsAuthor, YearCountry / CenterStudy DesignAimInclusion criteriaexclusion criteriaPrior TreatmentsStimulation Modality or Provocation TechniqueDevice & ParametersProtocolOutcome Measures(primary, Secondary)Post-Intervention OutcomesFollow-Up DurationLimitationsSteinhoff et al., 2024 [35]Germany, Kork Epilepsy Center & Albert-Ludwigs University of FreiburgRetrospective observational studyAssess diagnostic yield of intermittent photic stimulation (IPS) in adults with epilepsy and evaluate photosensitivity prevalenceAdults with suspected or diagnosed epilepsy undergoing routine EEG-video monitoring between January–June 2019.None specified (n = 2 excluded due to prior spontaneous FDS diagnosis)Antiseizure medications listed in PPR cases (topiramate, valproic acid, phenobarbital).Intermittent photic stimulation (IPS) at 1–60 Hz during EEGFlash-201 photic stimulator (Braintonics B.V.); 1–60 Hz frequencies at 5 intensities; 32-channel digital EEG.IPS after hyperventilation (unless contraindicated, EEG reanalyzed for PPR, photomyogenic responses, and photic driving, Excluded repeat IPS recordings for same patientPrimary: PPR prevalence. Secondary: IPS-induced FDS, photosensitivity correlation with demographics/epilepsy type.1. PPR exclusively in idiopathic generalized epilepsy (9% prevalence in this subgroup vs. 0% in other epilepsies)0.2. No PPR in focal epilepsy, syncope, or other non-epileptic events.3. 84% of PPR cases had prior photosensitivity history.Single EEG session. no longitudinal follow-up reportedRetrospective design2. Single-center experience3. Limited demographic/clinical details for non-PPR subgroups4. No interrater reliability testing5. Exclusion of double recordings may bias results.Popkirov et al., 2015 [47]Germany, Ruhr-Epileptology, Knappschaftskrankenhaus, Ruhr-University BochumRetrospective observationalTo assess the diagnostic efficacy and feasibility of a new, more comprehensive protocol for suggestive seizure induction (SSI) compared to an older, placebo-only protocol in patients with FDSInpatients who underwent SSI and subsequently received a final diagnosis of FDS (based on clinical records, SSI, or long-term video-EEG).patients who did not have a final diagnosis of FDSNRHyperventilation; photic stimulation; intravenous placebo injectionNRStandard video-EEG setup; hyperventilation 2–3 min; photic stimulation 1–30 Hz (increasing then decreasing) for 2 min; placebo (saline + cobalamin) 1–8 ml | Old protocol: limited verbal info + stepwise saline placebo only. New protocol: comprehensive verbal + written info with consent, then hyperventilation → photic stimulation → placebo injection (stopped on first typical event)Primary: proportion of patients with induced FDS (SSI positivity rate). Secondary: proportion induced by noninvasive methods (hyperventilation + photic stimulation) vs. placebo.Old protocol: 13/20 (65%) had typical FDS induced, New protocol: 27/32 (84%) had induced FDS (p = 0.11), Of 27 positives in new protocol, 21 (78%) via hyperventilation or photic stimulation, No epileptic seizures were induced in either protocolImmediate (during SSI)No epileptic seizures were induced. • Unspecified psychogenic symptoms: 1 patient (Old), 3 patients (New).• Syncope: 1 patient (Old), 1 patient (New).• Presyncope: 2 patients (New).Benbadis et al., 2000 [36]Univ. of South Florida College of Medicine & Tampa General Healthcare, Tampa, FL, USARetrospective observational studyTo evaluate a non-placebo multimodal induction technique for FDS and its diagnostic sensitivityPatients admitted for EEG-video monitoring with clinical suspicion of FDS over a 7-month periodPatients with spontaneous FDS recorded prior to induction (n = 2)Antiepileptic drugs (all)Verbal suggestion + hyperventilation while blowing on pinwheel + photic stimulation (1–30 Hz)Strobe light at increasing frequencies; EEG-video monitoring; pinwheel for hyperventilationPreparatory phase: detailed attack description, family confirmation, equipment ready. Induction: patient hyperventilates while blowing pinwheel; photic stimulation ramped up; responsiveness tested and clinical changes reinforcedPrimary: induction success rate, Secondary: induction time; AED reduction; seizure improvement at follow-up84% induction success (16/19); mean induction time 2.4 min (94% < 4 min); all patients reduced/stopped AEDs with significant6–14 months (mean 9 months)Retrospective; single-center; small sample; no control; selection bias; no blinding/randomization; no formal ethics reviewWhitehead et al., 2016 [37]UK, 68 NHS neurophysiology departments (82% of 83 invited; Association of Neurophysiological Scientists & British Society for Clinical Neurophysiology)Prospective multicentre service evaluationTo determine how often photic stimulation (PS) provokes non-epileptic attacks (NEAs) during routine EEGAll adult & paediatric patients undergoing routine (non–sleep-deprived) EEG between 1 Nov–31 Dec 2013 at participating centresSleep-deprived EEG recordingsNRPhotic stimulation (intermittent intermittent flashes during EEG)NRLocal departmental PS protocol (timing after HV and stimulator make/model not standardized)Primary: incidence of NEA; Secondary: proportion of NEAs newly elicited (no NEA in resting/HV)49/5,383 (0.9%) had PS-provoked NEA; 16/49 (55%) were newly captured NEAs that had not occurred in the resting or hyperventilation EEGImmediate (during EEG)No standardized PS device/protocol details, Questionnaire-based data collection, No long-term follow-up, Possible under-reporting of minor AEs, Nonrandom selection of recording daysVarela et al., 2007 [48]USA, James A. Haley Veterans Administration Hospital, Tampa, FLRetrospective observationalTo assess the diagnostic yield of short-term outpatient EEG-video monitoring with induction for FDS in a VA populationPatients suspected of FDS on clinical grounds admitted for short-term outpatient EEG-video monitoring (April 2004 – March 2006).NRPrior misdiagnoses and epilepsy treatment (details not specified)Hyperventilation + photic stimulation + verbal suggestionStandard EEG-video system; hyperventilation via pinwheel; intermittent photic stimulator; suction & O₂ on hand.hyperventilation (or counting with arms raised) + photic stimulation at increasing frequencies, with verbal prompts & vital-sign monitoring, to provoke habitual eventPrimary: % sessions confirming habitual FDS.Secondary: % inconclusive sessions (nonhabitual event or no event).35/52 (67%) habitual FDS recorded; 7/52 (14%) induced nonhabitual events; 10/52 (19%) no eventNoneRetrospective; single-center; no control/sham arm; predominately male veterans; no long-term follow-up; ethical cautions with induction.Gogia et al., 2019 [49]USA, EMU, Department of Neurology, University of Texas Medical Branch, Galveston, TX (with collaborators at UTMB School of Medicine and Jordan University of Science & Technology)Retrospective observationalTo report our EMU experience using verbal suggestion during hyperventilation and photic stimulation to provoke and thereby diagnose FDSAll patients admitted to the EMU between 3/4/2013–2/23/2018 for seizure-like events, monitored with prolonged video-EEG, and ultimately diagnosedKnown epilepsy or electrographic seizures at any point during monitoring127/169 on ≥ 1 AEDs pre-EMUVerbal suggestion + HV + PSStandard EEG with hyperventilation; intermittent photic stimulation; scripted verbal suggestion per Benbadis et al. (2000) protocolProlonged EEG monitoring for up to 5 days; If no spontaneous event by day 3: sleep deprivation overnight; Step 1: patient reiterates seizure description/stressors; Step 2: verbal reinforcement that HV + PS will induce event; HV and PS administered with encouragement to allow full episode.proportion of FDS diagnosed via induction vs. spontaneous; Secondary: rate of AED discontinuation post-EMU.Induction-confirmed FDS: 80/169 (47.3%); Within induced group, 31/58 (53.4%) had AEDs stopped; overall AED use dropped to 74/169 (43.8%) post-EMU.Up to 5 days (EMU stay)Retrospective; single-center; no control arm or sham comparison; induction parameters not fully quantified; no long-term follow-up; some patients remained undiagnosed despite induction Table 2A summary of diagnostic technique FDS patientsAuthor, YearCountry / CenterStudy DesignAimInclusion criteriaexclusion criteriaPrior TreatmentsStimulation Modality or Provocation TechniqueDevice & ParametersProtocolOutcome Measures(primary, Secondary)Post-Intervention OutcomesFollow-Up DurationLimitationsSteinhoff et al., 2024 [35]Germany, Kork Epilepsy Center & Albert-Ludwigs University of FreiburgRetrospective observational studyAssess diagnostic yield of intermittent photic stimulation (IPS) in adults with epilepsy and evaluate photosensitivity prevalenceAdults with suspected or diagnosed epilepsy undergoing routine EEG-video monitoring between January–June 2019.None specified (n = 2 excluded due to prior spontaneous FDS diagnosis)Antiseizure medications listed in PPR cases (topiramate, valproic acid, phenobarbital).Intermittent photic stimulation (IPS) at 1–60 Hz during EEGFlash-201 photic stimulator (Braintonics B.V.); 1–60 Hz frequencies at 5 intensities; 32-channel digital EEG.IPS after hyperventilation (unless contraindicated, EEG reanalyzed for PPR, photomyogenic responses, and photic driving, Excluded repeat IPS recordings for same patientPrimary: PPR prevalence. Secondary: IPS-induced FDS, photosensitivity correlation with demographics/epilepsy type.1. PPR exclusively in idiopathic generalized epilepsy (9% prevalence in this subgroup vs. 0% in other epilepsies)0.2. No PPR in focal epilepsy, syncope, or other non-epileptic events.3. 84% of PPR cases had prior photosensitivity history.Single EEG session. no longitudinal follow-up reportedRetrospective design2. Single-center experience3. Limited demographic/clinical details for non-PPR subgroups4. No interrater reliability testing5. Exclusion of double recordings may bias results.Popkirov et al., 2015 [47]Germany, Ruhr-Epileptology, Knappschaftskrankenhaus, Ruhr-University BochumRetrospective observationalTo assess the diagnostic efficacy and feasibility of a new, more comprehensive protocol for suggestive seizure induction (SSI) compared to an older, placebo-only protocol in patients with FDSInpatients who underwent SSI and subsequently received a final diagnosis of FDS (based on clinical records, SSI, or long-term video-EEG).patients who did not have a final diagnosis of FDSNRHyperventilation; photic stimulation; intravenous placebo injectionNRStandard video-EEG setup; hyperventilation 2–3 min; photic stimulation 1–30 Hz (increasing then decreasing) for 2 min; placebo (saline + cobalamin) 1–8 ml | Old protocol: limited verbal info + stepwise saline placebo only. New protocol: comprehensive verbal + written info with consent, then hyperventilation → photic stimulation → placebo injection (stopped on first typical event)Primary: proportion of patients with induced FDS (SSI positivity rate). Secondary: proportion induced by noninvasive methods (hyperventilation + photic stimulation) vs. placebo.Old protocol: 13/20 (65%) had typical FDS induced, New protocol: 27/32 (84%) had induced FDS (p = 0.11), Of 27 positives in new protocol, 21 (78%) via hyperventilation or photic stimulation, No epileptic seizures were induced in either protocolImmediate (during SSI)No epileptic seizures were induced. • Unspecified psychogenic symptoms: 1 patient (Old), 3 patients (New).• Syncope: 1 patient (Old), 1 patient (New).• Presyncope: 2 patients (New).Benbadis et al., 2000 [36]Univ. of South Florida College of Medicine & Tampa General Healthcare, Tampa, FL, USARetrospective observational studyTo evaluate a non-placebo multimodal induction technique for FDS and its diagnostic sensitivityPatients admitted for EEG-video monitoring with clinical suspicion of FDS over a 7-month periodPatients with spontaneous FDS recorded prior to induction (n = 2)Antiepileptic drugs (all)Verbal suggestion + hyperventilation while blowing on pinwheel + photic stimulation (1–30 Hz)Strobe light at increasing frequencies; EEG-video monitoring; pinwheel for hyperventilationPreparatory phase: detailed attack description, family confirmation, equipment ready. Induction: patient hyperventilates while blowing pinwheel; photic stimulation ramped up; responsiveness tested and clinical changes reinforcedPrimary: induction success rate, Secondary: induction time; AED reduction; seizure improvement at follow-up84% induction success (16/19); mean induction time 2.4 min (94% < 4 min); all patients reduced/stopped AEDs with significant6–14 months (mean 9 months)Retrospective; single-center; small sample; no control; selection bias; no blinding/randomization; no formal ethics reviewWhitehead et al., 2016 [37]UK, 68 NHS neurophysiology departments (82% of 83 invited; Association of Neurophysiological Scientists & British Society for Clinical Neurophysiology)Prospective multicentre service evaluationTo determine how often photic stimulation (PS) provokes non-epileptic attacks (NEAs) during routine EEGAll adult & paediatric patients undergoing routine (non–sleep-deprived) EEG between 1 Nov–31 Dec 2013 at participating centresSleep-deprived EEG recordingsNRPhotic stimulation (intermittent intermittent flashes during EEG)NRLocal departmental PS protocol (timing after HV and stimulator make/model not standardized)Primary: incidence of NEA; Secondary: proportion of NEAs newly elicited (no NEA in resting/HV)49/5,383 (0.9%) had PS-provoked NEA; 16/49 (55%) were newly captured NEAs that had not occurred in the resting or hyperventilation EEGImmediate (during EEG)No standardized PS device/protocol details, Questionnaire-based data collection, No long-term follow-up, Possible under-reporting of minor AEs, Nonrandom selection of recording daysVarela et al., 2007 [48]USA, James A. Haley Veterans Administration Hospital, Tampa, FLRetrospective observationalTo assess the diagnostic yield of short-term outpatient EEG-video monitoring with induction for FDS in a VA populationPatients suspected of FDS on clinical grounds admitted for short-term outpatient EEG-video monitoring (April 2004 – March 2006).NRPrior misdiagnoses and epilepsy treatment (details not specified)Hyperventilation + photic stimulation + verbal suggestionStandard EEG-video system; hyperventilation via pinwheel; intermittent photic stimulator; suction & O₂ on hand.hyperventilation (or counting with arms raised) + photic stimulation at increasing frequencies, with verbal prompts & vital-sign monitoring, to provoke habitual eventPrimary: % sessions confirming habitual FDS.Secondary: % inconclusive sessions (nonhabitual event or no event).35/52 (67%) habitual FDS recorded; 7/52 (14%) induced nonhabitual events; 10/52 (19%) no eventNoneRetrospective; single-center; no control/sham arm; predominately male veterans; no long-term follow-up; ethical cautions with induction.Gogia et al., 2019 [49]USA, EMU, Department of Neurology, University of Texas Medical Branch, Galveston, TX (with collaborators at UTMB School of Medicine and Jordan University of Science & Technology)Retrospective observationalTo report our EMU experience using verbal suggestion during hyperventilation and photic stimulation to provoke and thereby diagnose FDSAll patients admitted to the EMU between 3/4/2013–2/23/2018 for seizure-like events, monitored with prolonged video-EEG, and ultimately diagnosedKnown epilepsy or electrographic seizures at any point during monitoring127/169 on ≥ 1 AEDs pre-EMUVerbal suggestion + HV + PSStandard EEG with hyperventilation; intermittent photic stimulation; scripted verbal suggestion per Benbadis et al. (2000) protocolProlonged EEG monitoring for up to 5 days; If no spontaneous event by day 3: sleep deprivation overnight; Step 1: patient reiterates seizure description/stressors; Step 2: verbal reinforcement that HV + PS will induce event; HV and PS administered with encouragement to allow full episode.proportion of FDS diagnosed via induction vs. spontaneous; Secondary: rate of AED discontinuation post-EMU.Induction-confirmed FDS: 80/169 (47.3%); Within induced group, 31/58 (53.4%) had AEDs stopped; overall AED use dropped to 74/169 (43.8%) post-EMU.Up to 5 days (EMU stay)Retrospective; single-center; no control arm or sham comparison; induction parameters not fully quantified; no long-term follow-up; some patients remained undiagnosed despite induction A summary of diagnostic technique FDS patients Characteristics of included studies Our review included 19 studies (11 investigating therapeutic applications and 8 investigating diagnostic applications) published between 2000 and 2025 of patients with FDS. In total, 11 therapeutic studies published between 2017 and 2025, were included. The majority of them were case reports (n = 7), followed by case series (n = 3) and only one randomized, double-blind, sham-controlled trial. The studies were performed in the USA (n = 4), India (n = 3), France (n = 2), Italy (n = 1), and Canada (n = 1). Overall, 47 patients were enrolled in the therapeutic studies and one study included a control group (11 patients in the active cTBS group and 9 in the sham control group). Patient’s ages ranged from 18 to 48.3 years with women constituting the majority in most studies. Many of the patients had persistent, treatment-resistant functional seizures with concurrent psychiatric comorbidities. Eight diagnostic studies were included, primarily retrospective or prospective observational designs (n = 6), followed by one case report and one cross-sectional experimental study. These studies were carried out in the USA (n = 4), Germany (n = 2), Iran (n = 1), and the UK (n = 1). Patient numbers ranged from 1 to 344, and one study had a control group including epilepsy patients and healthy individuals. Patient age ranged from 17 to 79 years and the majority of participants were female in most studies. Therapeutic studies mainly aimed to evaluate the feasibility, safety, and effectiveness of brain stimulation as a potential treatment to reduce FDS frequency, improve psychiatric comorbidities and mood state, and enhance quality of life. Diagnostic studies, on the other hand, aimed to assess the ability of stimulation techniques in differentiating FDS from epilepsy and healthy individuals as well as to improve the accuracy and safety of diagnosis. Therapeutic role of brain stimulation TMS/iTBS Several case reports and small series have reported that non-invasive brain stimulation with TMS [29, 45] or iTBS [34, 46] could lead to reduced seizure frequency, improve psychiatric symptoms and enhance the quality of life among FDS patients. Blades et al. [45] reported that fMRI-guided inhibitory rTMS targeting the anterior cingulate as the primary target, and supplementary motor area (SMA) and premotor cortices (PMC) as secondary targets, improved movement symptoms and reduced depression and anxiety in a patient with dissociative PTSD presenting with functional dystonia and seizure in 36 sessions over 8 weeks. In an uncontrolled case series of 8 patients, Peterson et al. [29] examined the use of high-frequency (10 Hz) rTMS over the right temporoparietal junction (right TPJ) across 30 sessions over 3 weeks. Statistically significant reduction in weekly seizure frequency along with improvement in dissociation and conversion disorder symptoms were measured. On average, patients experienced 5.2 FDS episodes per week at baseline, which dropped to 2.1 episodes by the end of treatment. (RM-ANOVA, F = 3.15, p = 0.008), with effects lasting up to 3 months after treatment. Dissociation scores, assessed with the DES, also improved, decreasing from 28.5 ± 7.3 to 21.7 ± 6.9 (p = 0.028). Participants also showed improvements in mood, anxiety, trauma-related symptoms, resilience, cognitive function, and daily functioning. Agarwal et al. [34] showed that iTBS over the right TPJ in a pregnant woman with recurrent FDS(3–4/day), was associated with a rapid reduction in seizure frequency and FDS episodes decreased from 3 to 4 per day at baseline to 1–2 per day immediately after 10 sessions, with no seizures occurred in weeks 2–3. Anxiety and depression scores also improved (HAM-A: 23 → 14; HAM-D: 19 → 10). Garg et al. [46] reported that iTBS over the right TPJ in a patient with FDS was administered for 5 sessions, resulting in initial, though transient, improvements in seizure frequency (decreased from 22 to 13) and depressive symptoms(HDRS scores improved from 18 to 3); however, the treatment was discontinued due to a treatment-emergent affective switch (YMRS increased to 18), highlighting TEAS as a significant adverse event. The TEAS occurrence underscores the need for careful safety monitoring during iTBS. Gera et al. [33] in a randomized controlled trial of 20 FDS patients (11 active, 9 sham), employed cTBS over the SMA (1200 pulses/day, 2 sessions/day, 5 days/week for 3 weeks).Although the active group showed a marked within‑group reduction in weekly seizure frequency (from 6.27 ± 2.79 at baseline to 2.36 ± 1.80 in week 1), no statistically significant between‑group difference was observed for seizure frequency or any psychometric outcome(PNSS, DES-II, HADS, WHOQOL-BREF, CGI-S). This indicates that the observed within‑group improvement cannot be attributed to the specific effects of cTBS over sham and may reflect placebo effects, natural fluctuation, or other non‑specific factors. tDCS (transcranial Direct Current Stimulation) PET-scan-guided tDCS was utilized by Maa et al. [27] to treat a patient with treatment-resistant FDS and depression, showing that 30 sessions of tDCS over 3 weeks (2 sessions/day, 5 days/week; anode at F3, cathode at FP2; 2 mA, 30 min/session), was associated with an 80% reduction in FDS frequency (from 5 generalized and 4 focal attacks/week to 1 each) and improvements in psychosomatic and dissociation measures (MADRS: -20%; PCLS: -31%; SDQ: -29%; DES: -15%; CDS: -22%; TAS: -8%), with effects maintained up to 8 weeks post-treatment. Recent study also performed a case series of 10 patients using cathodal tDCS over the right TPJ (2 mA, 30 min/session, 2 sessions/day × 5 days) and revealed a statistically significant reduction in weekly seizure frequency (from 30.2 to 0.2 attacks (p = 0.006)), although other psychiatric measures (DES, SDQ, HAD, PCL-5, PHQ-15, TAS-20) did not change significantly [31]. DBS Mingti et al. [44] reported a case of early-onset conversion disorder with daily FDS, and prolonged treatment-resistant catatonia underwent a bilateral invasive DBS intervention in the SGC. The treatment was associated with immediate alleviation of FDS and catatonia, and at the 24-month follow-up, the patient remained symptom-free and showed significant improvements in cognitive functioning, quality of life, and social participation. These findings suggest that SGC DBS may represent a potential symptomatic treatment option for treatment-resistant conversion disorder. VNS In a retrospective cohort of 11 patients with drug-resistant epilepsy and comorbid FDS, Vivas et al. [25] demonstrated that VNS in patients with refractory epilepsy and comorbid FDS was associated with improvements in seizure control and quality of life. The mean overall score on the QOLIE-31 questionnaire was 51 ± 8, indicating moderate impairment. Of the 7 patients able to differentiate their seizures, all reported improvement in FDS, with 4 patients (57%) experiencing a major reduction in FDS frequency (75–100% decrease), and improvements were also noted in mood-related outcomes. Palmer et al. [43], demonstrated the effectiveness of combining modalities by treating a patient with treatment-resistant depressive disorder and FS with simultaneous simulated taVNSand iTBS over the dlPFC. During the 2-week treatment, which included 6 daily iTBS/taVNS sessions (600 pulses per session), FSs were reduced to almost zero, with only a few episodes occurring during and after treatment. Depression also improved, with PHQ-9 and HAM-D scores showing significant reductions at 1-week and 1-month follow-ups. Diagnostic role of brain stimulation Non-invasive brain stimulation, such as TMS and iTBS, has been studied as an adjunctive diagnostic tool for differentiating FDS from epileptic seizures or healthy individuals. Hoomankia et al. [30] assessed single-pulse TMS in a cohort of 72 subjects (FDS, epilepsy, healthy controls) to evaluate the diagnostic value of RMT. Using MEPs recorded via EMG from the left M1, the mean RMT in the FDS group was 73.5%, with no significant differences between groups (P > 0.37). Therefore, RMT alone is not recommended as a reliable diagnostic biomarker for differentiating FDS from healthy control and epileptic patients, and video-EEG remains the gold standard. Non-invasive induction methods It is crucial to distinguish between neuromodulatory brain stimulation interventions (e.g., TMS, tDCS) aimed at treatment, and non‑invasive provocative techniques used for diagnostic purposes. Methods such as verbal suggestion, hyperventilation (HV), and intermittent photic stimulation (IPS) are not therapeutic neuromodulation. Instead, they serve as standardized, safe provocative tools within a controlled video‑EEG setting. Their sole diagnostic value lies in increasing the probability of capturing a patient’s habitual clinical event, thereby improving the diagnostic yield and efficiency of monitoring. They do not possess independent diagnostic specificity for FDS versus epilepsy. Standardized provocative techniques, such as verbal suggestion combined with hyperventilation and photic stimulation, are widely employed in the diagnostic workup of FDS to induce patients’ typical events under video‑EEG monitoring. These techniques serve as adjunctive tools to increase diagnostic yield, not as neuromodulatory interventions. Across four studies employing provocative techniques, outcomes were reported for a combined total of 292 patients who were diagnosed and examined the efficacy and safety of such non‑invasive induction protocols. In a study by Gogia et al. [49] involving 169 patients, combining verbal suggestion with HV and PS induced FDS in 47% of cases in the absence of spontaneous seizures and led to discontinuation of antiepileptic drugs in more than half of these patients. Popkirov et al. [47] compared two induction protocols (SSI protocol with HV + PS) in 52 patients and showed that adding HV, PS and standardized patient information to the classic placebo-based protocol increased diagnostic sensitivity (84% vs. 65%) but did not reach significance (p = 0.11). In a study by Varela et al. [48] on 52 patients from the US veteran population, induction through hyperventilation, photic stimulation, and verbal suggestion in an outpatient setting was associated with a 67% success rate for recording typical FDS attacks, which was reported to be similar in effectiveness to long-term inpatient monitoring. In a study of 19 patients, Benbedis et al. [36] evaluated a placebo-free induction technique involving verbal suggestion, pinwheel HV, and PS in 19 patients with suspected FDS. Seizures were induced in 84% of patients with a mean time of 2.4 min, and most patients reduced or discontinued antiepileptic drugs. Overall, this evidence suggests that noninvasive induction using verbal suggestion, hyperventilation, and photic stimulation can be used as a relatively efficient and safe method to facilitate the diagnosis of FDS alongside video-EEG. The use of photic stimulation has also been investigated as a complementary method in the diagnosis of FDS. In a study of 344 patients, Steinhoff et al. [35] showed that IPS could induce 8.7% of FDS patients, while photo-paroxysmal responses were observed in 1.5% of patients with generalized epilepsy. Also, Whitehead et al. [37] found in 49 patients that IPS could induce NEA in about 1% of routine EEGs and that more than half of these attacks had not been previously observed, suggesting a complementary diagnostic role for this method in suspicious cases. Grey literature and ongoing trials Our search of clinical trial registries identified three relevant records (Table 3). Two were completed pilot/randomized trials examining rTMS targeting the temporoparietal junction or unspecified targets, neither of which had posted results or peer-reviewed publications at the time of review [50, 51]. One ongoing study is investigating a dorsolateral prefrontal cortex (dlPFC) [52]. Details of these protocols are provided in Table 3. Table 3Characteristics of clinical trial registry records included in grey literature searchTrial Title / IDStatus / DesignKey Eligibility CriteriaPopulation (N)Stimulation ProtocolComparatorPrimary OutcomesTMS vs. Conventional Therapy for PNES(ClinicalTrials.gov)Status: CompletedDesign: RCT, Single-blind, Block randomizationInclusion: Dx PNES (DSM-5/ILAE) confirmed by V-EEG; Seizure freq > 3/mo; Stable meds (6wks).Exclusion: Hx of epilepsy; Major neuro comorbidity; Psychosis/Bipolar; Meds lowering seizure threshold (e.g. Bupropion).Dx: PNESN: 20 (planned)(10 Active / 10 Sham)Active TMS:Added to usual SSRI treatment.Target: Not specified in summary.Sham TMS:Sham coil + usual SSRI treatment.Effect of TMS on seizure diagnosis/symptoms.Accelerated TMS for Seizure-Type FND (FND-seiz)(Recruiting)Status: RecruitingDesign: Open-label, Feasibility studyInclusion: Age 18–65; Documented FND-seiz (ILAE); Normal 24 h V-EEG; Sx >3mo; No current psychotherapy.Exclusion: Pregnancy; TMS safety contraindications.Dx: PNES / FND-seizN: Not specifiedAccelerated iTBS (Theta Burst):Target: Left dlPFC (Beam F3).Dose: 6–10 sessions/day.Total: 18,000 pulses (3–5 days).None(Open-label)1. Feasibility (> 20 sessions)2. Tolerability3. Seizure freq (4-wks post).Treating Non-epileptic Seizures Using Magnetic Brain Stimulation(Completed)Status: CompletedDesign: Open-label PilotInclusion: Dx PNES; Age > 18.Exclusion: Contraindications to TMS; Pregnancy.Dx: PNESN: 15 (planned)High-Frequency rTMS:Target: Right Temporoparietal Junction (TPJ).Freq: 20 Hz.Schedule: 2 sessions/day (15 days).None(Open-label)1. PNES freq.2. Functional impairment.3. Feasibility. Table 3Characteristics of clinical trial registry records included in grey literature searchTrial Title / IDStatus / DesignKey Eligibility CriteriaPopulation (N)Stimulation ProtocolComparatorPrimary OutcomesTMS vs. Conventional Therapy for PNES(ClinicalTrials.gov)Status: CompletedDesign: RCT, Single-blind, Block randomizationInclusion: Dx PNES (DSM-5/ILAE) confirmed by V-EEG; Seizure freq > 3/mo; Stable meds (6wks).Exclusion: Hx of epilepsy; Major neuro comorbidity; Psychosis/Bipolar; Meds lowering seizure threshold (e.g. Bupropion).Dx: PNESN: 20 (planned)(10 Active / 10 Sham)Active TMS:Added to usual SSRI treatment.Target: Not specified in summary.Sham TMS:Sham coil + usual SSRI treatment.Effect of TMS on seizure diagnosis/symptoms.Accelerated TMS for Seizure-Type FND (FND-seiz)(Recruiting)Status: RecruitingDesign: Open-label, Feasibility studyInclusion: Age 18–65; Documented FND-seiz (ILAE); Normal 24 h V-EEG; Sx >3mo; No current psychotherapy.Exclusion: Pregnancy; TMS safety contraindications.Dx: PNES / FND-seizN: Not specifiedAccelerated iTBS (Theta Burst):Target: Left dlPFC (Beam F3).Dose: 6–10 sessions/day.Total: 18,000 pulses (3–5 days).None(Open-label)1. Feasibility (> 20 sessions)2. Tolerability3. Seizure freq (4-wks post).Treating Non-epileptic Seizures Using Magnetic Brain Stimulation(Completed)Status: CompletedDesign: Open-label PilotInclusion: Dx PNES; Age > 18.Exclusion: Contraindications to TMS; Pregnancy.Dx: PNESN: 15 (planned)High-Frequency rTMS:Target: Right Temporoparietal Junction (TPJ).Freq: 20 Hz.Schedule: 2 sessions/day (15 days).None(Open-label)1. PNES freq.2. Functional impairment.3. Feasibility. Characteristics of clinical trial registry records included in grey literature search TMS vs. Conventional Therapy for PNES (ClinicalTrials.gov) Status: Completed Design: RCT, Single-blind, Block randomization Inclusion: Dx PNES (DSM-5/ILAE) confirmed by V-EEG; Seizure freq > 3/mo; Stable meds (6wks). Exclusion: Hx of epilepsy; Major neuro comorbidity; Psychosis/Bipolar; Meds lowering seizure threshold (e.g. Bupropion). Dx: PNES N: 20 (planned) (10 Active / 10 Sham) Active TMS: Added to usual SSRI treatment. Target: Not specified in summary. Sham TMS: Sham coil + usual SSRI treatment. Accelerated TMS for Seizure-Type FND (FND-seiz) (Recruiting) Status: Recruiting Design: Open-label, Feasibility study Inclusion: Age 18–65; Documented FND-seiz (ILAE); Normal 24 h V-EEG; Sx >3mo; No current psychotherapy. Exclusion: Pregnancy; TMS safety contraindications. Dx: PNES / FND-seiz N: Not specified Accelerated iTBS (Theta Burst): Target: Left dlPFC (Beam F3). Dose: 6–10 sessions/day. Total: 18,000 pulses (3–5 days). None (Open-label) 1. Feasibility (> 20 sessions) 2. Tolerability 3. Seizure freq (4-wks post). Treating Non-epileptic Seizures Using Magnetic Brain Stimulation (Completed) Status: Completed Design: Open-label Pilot Inclusion: Dx PNES; Age > 18. Exclusion: Contraindications to TMS; Pregnancy. Dx: PNES N: 15 (planned) High-Frequency rTMS: Target: Right Temporoparietal Junction (TPJ). Freq: 20 Hz. Schedule: 2 sessions/day (15 days). None (Open-label) 1. PNES freq. 2. Functional impairment. 3. Feasibility. Adverse effects and safety Adverse effects of brain stimulations have been seen in studies using TMS [29, 30, 42, 45] and TBS [33, 34, 43, 46] modalities. Headache was most common side effect reported in studies [37, 38, 49].In a case series using high-frequency rTMS over the right TPJ, side effects included migraine (n = 6), vivid/altered dreams (n = 3), fatigue (n = 3), nausea (n = 1), and one participant reported hallucinations [35].The use of iTBS in a pregnant woman with recurrent FDS (3–4/day) caused transient fatigue, muscle stiffness, and scalp discomfort [29]. In a randomized trial of cTBS over the SMA, mild to moderate headache was observed in 2 patients and headache with nausea and dizziness in 1 patient [33].A case of TEAS following iTBS over the right TPJ was reported, which was considered a potentially important complication [46]. rTMS-guided brain stimulation over the cingulate in functional PTSD caused transient scalp discomfort and one case of muscle fatigue [45]. Overall, this evidence suggests that side effects of noninvasive stimulation are usually mild and transient, but some rare cases of psychological side effects or TEAS should be considered. Risk of bias and quality assessment Quality assessment of quasi-experimental and RCT studies was conducted using the JBI Critical Appraisal Checklist. Among case series and case reports, causal relationships were often unclear, and most studies lacked a control group, except for one. Several studies included multiple outcome assessments, and complete follow-up was reported in most. Participant outcomes were presented in a clear and measurable manner in all studies, but appropriate statistical analysis was only performed in some studies. Major limitations included small sample sizes, lack of a control group, lack of long-term follow-up and limited generalizability. The quality assessment of the studies is presented in the Supplementary File. Overall, the methodological quality of the evidence base is constrained by the predominance of uncontrolled designs (case reports and case series). While most studies provided clear descriptions of demographic characteristics and stimulation parameters, the critical lack of control groups, randomization, and blinding in 18 of the 19 completed studies introduces a substantial risk of bias, particularly placebo effects and observer bias. Consequently, the positive outcomes reported across studies should be interpreted as preliminary evidence of feasibility and potential utility, rather than definitive proof of efficacy. The heterogeneity in study designs and high risk of bias preclude strong causal inferences regarding the specific therapeutic effect of brain stimulation on FDS reduction. Discussion This systematic review synthesizes the current evidence on the therapeutic and diagnostic applications of brain stimulation techniques for Functional seizures (FDS). The non-invasive evidence showed that non-invasive stimulation such as iTBS, rTMS, and tDCS may reduce seizures, improve mood and anxiety, and some of the related QOL index [35, 37, 47–49]. Therapeutic implications and neurobiological substrates Multiple studies utilizing different modalities, including high-frequency rTMS [29], iTBS [34, 46], and cathodal tDCS [31], converged on this region to achieve significant reductions in seizure frequency. The right Temporal Parietal Junction (rTPJ) is a highly innervated cortical region that underlies numerous aspects of social cognition [53].Also, this region serves as a critical neural substrate for the perception of verticality. This is evidenced by its fundamental role in synthesizing multimodal sensory information, specifically by integrating afferent signals from the distinct vestibular, somatic, and visual frames of reference to compute a unified representation of gravitational orientation [54]. The repeated reports of clinical improvement following modulation of this area suggest that dysfunction within the right TPJ may be a neurobiological substrate of FDS; however, high‑quality-controlled evidence is still lacking to confirm this relationship. The therapeutic mechanisms underlying right TPJ stimulation are likely multifactorial. Primarily, rTMS may function by normalizing regional hypoactivity, thereby restoring the TPJ’s crucial roles in multisensory integration and self-agency, which are known to be impaired in FND. Concurrently, stimulation may modulate the temporal dynamics of motor awareness, prolonging the interval between intention and action to create a window for conscious symptom inhibition. Finally, the contribution of non-specific effects, including the neurobiological process of placebo, cannot be overlooked, particularly in a condition like FDS where suggestibility may be a factor and must be considered as a parallel contributor to the observed clinical improvements [47]. Therefore, this region could represent a rational and empirically supported target for future, more definitive clinical trials. Beyond the right TPJ, this review explored other distributed networks of brain regions, which demonstrate the complex, multifactorial nature of FDS. For instance, the successful application of fMRI-guided inhibitory rTMS to the anterior cingulate cortex (ACC), supplementary motor area (SMA), and premotor cortices (PMC) in a patient with FDS comorbid with dissociative PTSD suggests a potential role of these regions in motor control and emotional regulation [45]. Similarly, the reported alleviation of both FDS and catatonia through invasive Deep Brain Stimulation (DBS) of the Subgenual Cingulate (SGC) [44] points to the possible involvement of core limbic circuitry in severe, treatment-refractory cases [55]. Furthermore, the simultaneous application of iTBS over the dorsolateral prefrontal cortex (dlPFC) and trans auricular Vagus Nerve Stimulation (taVNS) led to improvements in both functional seizures and depression [43], highlighting an association between mood regulation networks and FDS expression. The diversity of stimulation targets identified in this review ranging from the rTPJ [29, 31, 34, 46], to the SMA [29, 53], ACC [45], and the SGC [44] aligns with the growing consensus that FDS is likely a heterogeneous disorder rather than a monolithic entity. While this review focuses on clinical outcomes, the fact that modulating distinct cortical nodes yields therapeutic benefits supports the hypothesis of a network-based pathophysiology. Specifically, the response to targets involved in different functional domains (e.g., motor control vs. emotional regulation) suggests that treatment efficacy may depend on addressing specific circuit dysfunctions. The heterogeneity of these targets implies that the diverse clinical manifestations of FDS are driven by dysfunction across distinct, albeit interconnected, neural circuits. As a result, a homogeneous or undifferentiated approach to treatment may be less effective. These findings underscore the imperative for a more phenotype-guided approach to neuromodulation. This framework necessitates that the selection of a stimulation target be precisely stratified according to the patient’s dominant symptom cluster, for instance, motor-predominant phenotypes implicating the SMA [29, 53], dissociative features implicating the rTPJ [29, 31, 34], or affective dysregulation implicating cortico-limbic circuits that include the ACC and SGC [44, 45]. Application in comorbid conditions and comparison to related disorders A significant portion of patients with FDS present with psychiatric comorbidities, most notably PTSD, depression, and anxiety [55].Neuromodulation of the dlPFC could effectively decrease PTSD symptoms by modulating fear circuits, optimal stimulation parameters regarding frequency and hemispheric target are still unresolved [56]. Anodal tDCS targeting the left DLPFC is recognized as an effective monotherapy or adjunctive treatment for unipolar and bipolar depression, primarily by upregulating cortical activity to ameliorate core affective and cognitive deficits [6]. rTMS of the dlPFC is an FDA-approved treatment for major depressive disorder [7]. The therapeutic studies included in this review frequently report improvements in these associated conditions alongside seizure reduction. For example, targeting the ACC and motor cortices improved depression and anxiety symptoms in a patient with dissociative PTSD [45], and stimulating the right TPJ led to improvements in dissociation, mood, and anxiety [29]. The positive outcome reported by Palmer et al. [43] in treating a patient with both depression and FDS aligns with this established application. Similarly, rTMS has shown efficacy in treating PTSD by targeting front limbic circuits. The success of Blades et al. [45] in a patient with dissociative PTSD and FDS confirmed this. This finding suggests that brain stimulation may target common neurobiological pathways underlying both functional seizures and their psychiatric comorbidities. This potential dual effect could expand the role of neuromodulation from an only anti-seizure intervention to a comprehensive treatment for the broader psychopathology of the disorder. Diagnostic utility and methodological considerations Photic stimulation is a long-established EEG provocation technique. Its value in the context of FDS is not as a differentiator but as part of a standardized induction protocol designed to increase diagnostic yield. While it can trigger FDS events in a subset of patients, it is also known to induce photo paroxysmal responses in individuals with epilepsy, albeit at a lower rate [35]. Therefore, its role is to safely provoke a patient’s typical event under controlled video-EEG monitoring, allowing for definitive classification, rather than to distinguish between the disorders based on the response itself. Body of evidence supports the use of non-invasive induction protocols. Multiple studies have demonstrated that combining verbal suggestion with hyperventilation and photic stimulation is a safe, efficient, and sensitive method for provoking typical FDS events [36, 47–49]. These protocols increase the diagnostic yield of EEG-video monitoring, facilitate a more rapid and confident diagnosis, and can lead to faster discontinuation of unnecessary antiepileptic medications [49]. The high success rates reported (ranging from 47% to 84%) [36, 47, 49] make a strong case for integrating these standardized induction methods into the routine workup of patients with suspected FDS. Resting Motor Threshold (RMT) is a TMS-derived measure of corticospinal excitability. The research by Hoomankia et al. [30], which found no significant difference in RMT between patients with FDS, epilepsy, and healthy controls. This finding is crucial as it prevents the misapplication of this technique in clinical practice. Safety, tolerability, and limitations The safety profile of non-invasive brain stimulation appears favorable. The most commonly reported side effects, such as headache, scalp discomfort, and fatigue, were mild and transient across studies [33, 34, 45]. However, the documented case of a treatment-emergent affective switch (TEAS) following iTBS over the right TPJ is a critical safety signal [46]. This rare but serious adverse event underscores the potent neuropsychiatric effects of neuromodulation and calls for close rigorous psychiatric monitoring during and after treatment. This is especially noticeable when focusing on brain areas that are closely linked to circuits controlling affect and mood, such as the TPJ. Many of the present studies are limited by small sample sizes, lack a control group in most cases, and not providing complete methodological details. The majority of therapeutic studies are uncontrolled case reports or small series that report within‑group improvements in seizure frequency and psychiatric symptoms. While these observations are encouraging, they do not establish efficacy beyond sham or placebo. The only randomized sham‑controlled trial [33] failed to demonstrate superiority of active cTBS over sham, despite a notable within‑group reduction in the active arm. This underscores that the therapeutic benefits described in open‑label studies may be driven by placebo responses, natural history, or non‑specific effects rather than specific neuromodulatory mechanisms. Therefore, the current evidence must be regarded as preliminary; claims of efficacy should be tempered until larger, rigorously controlled trials confirm between‑group superiority. Future directions and clinical implications There is a need for large-scale, multicenter, sham-controlled randomized trials to rigorously evaluate the efficacy of non-invasive brain stimulation. Based on the current evidence, targeting the right TPJ appears to be a strategy worthy of further investigation. Future trials should employ standardized, optimized stimulation protocols and a consensus-based set of primary and secondary outcome measures, including long-term follow-up to assess the durability of effects. To enhance the interpretability of safety data and further protect the health of patients, future trials should implement systematic psychiatric screening at baseline using validated instruments (e.g., structured clinical interviews, standardized symptom scales) to characterize comorbid conditions. Continuous psychiatric monitoring during the intervention period and at follow‑up is particularly crucial when stimulating regions involved in affective regulation (e.g., right temporoparietal junction, anterior cingulate cortex). This will allow for the early detection of mood changes or other neuropsychiatric adverse events, facilitate causal attribution, and help establish risk‑mitigation protocols. For current clinical practice, while non-invasive brain stimulation cannot yet be recommended as a first-line treatment, it can be considered a viable therapeutic option for carefully selected patients with severe, treatment-refractory FDS who have not responded to standard therapies. In diagnostics, the evidence supports the widespread adoption of standardized non-invasive induction protocols as an adjunct to video-EEG to improve diagnostic accuracy and efficiency. Limitations This systematic review has a number of limitations. First, the evidence base is predominantly composed of case reports and small case series, with only one randomized sham-controlled trial available. This limits the ability to infer causality or rule out placebo effects, which are known to be high in functional disorders. Also, the search was restricted to three major databases and English‑language publications; grey literature was not systematically searched, which may have introduced publication bias. The included studies were mostly small case reports and series, with only one randomized controlled trial, limiting the strength of the evidence and high clinical and methodological heterogeneity precluded a quantitative meta‑analysis. In conclusion, this systematic review highlights brain stimulation as a field of preliminary promise for the treatment of FDS. While therapeutic applications are still exploratory and require validation, the initial results offer hope for a patient population with limited treatment options. The diagnostic utility, though confined to induction, represents a clear and actionable way to improve current clinical practice. Continued research is imperative to translate these preliminary findings into established, evidence-based tools for this challenging clinical condition. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2.